

APPROVED DRUG PRODUCTS


With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)

**CUMULATIVE
SUPPLEMENT 03
March 2006**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

26th EDITION

Department of Health and Human Services

**Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs**

2006

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

26th EDITION

Cumulative Supplement 03

March 2006

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Applicant Name Changes.....	iv
1.3 Availability of the Edition	v
1.4 Report of Counts for the Prescription Drug Product List	vi
1.5 Cumulative Supplement Legend	vii
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

Note:

Historically, the Electronic Orange Book (EOB) and Cumulative Supplement (CS) have been updated monthly, each month updated by the end of the second full working week of the following month.

As of February 2005, we are also providing daily EOB product information for new generic drug approvals. Daily generic updates will provide the consumer with the most current listing of approved generic products. Previously, a first-time-generic approved early in the month would not be published in the CS for several weeks. Daily generic updates are especially important since the Orange Book listing may be relevant for substitution.

As a result, the monthly CS will include generic approvals and related product changes current to the day of publication (e.g., the June CS will include generic approvals up to the second week of July). Patent information is also current to the day of publication.

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

26th EDITION

CUMULATIVE SUPPLEMENT 03

March 2006

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 25th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 25th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 26th Edition. The current edition

Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

AVENTIS PHARMACEUTICALS INC
(AVENTIS)
AVENTIS PHARMACEUTICAL PRODUCTS INC
(AVENTIS PHARMS)

SANOFI AVENTIS US LLC
(SANOFI AVENTIS US)
SANOFI AVENTIS US LLC
(SANOFI AVENTIS US)

DERMIK LABORATORIES DIV AVENTIS PHARMACEUTICALS INC (DERMIK LABS)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
DERMIK LABORATORIES INC (DERMIK LABS)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
DERMIK LABORATORIES INC SUB RORER (DERMIK LABS)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
CLAY PARK LABORATORIES INC (CLAY PARK)	PERRIGO NEW YORK INC (PERRIGO NEW YORK)
CLAY PARK LABS INC (CLAY PARK)	PERRIGO NEW YORK INC (PERRIGO NEW YORK)
LOREX PHARMACEUTICALS (LOREX)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
MARTEC PHARMACEUTICALS (MARTEC)	MARTEC USA LLC (MARTEC USA LLC)
MARTEC SCIENTIFIC INC (MARTEC)	MARTEC USA LLC (MARTEC USA LLC)
PRIVATE FORMULATIONS INC (PRIVATE FMLTNS)	LEINER HEALTH PRODUCTS INC (LEINER HLTH PRODS)
PHARMACEUTICAL FORMULATIONS INC (PHARM FORM)	LEINER HEALTH PRODUCTS INC (LEINER HLTH PRODS)
SANOFI AVENTIS US INC (SANOFI AVENTIS US)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
SANOFI-AVENTIS US INC (SANOFI AVENTIS)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
SANOFI INC (SANOFI)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
SANOFI SYNTHELABO INC (SANOFI SYNTHELABO)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
SANOFI SYNTHELABO RESEARCH DIV SANOFI SYNTHELABO INC (SANOFI SYN RES)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
UCB PHARMA INC (UCB PHARMA)	UCB INC (UCB INC)

1.3 AVAILABILITY OF THE EDITION

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements will not be available in a published paper version. Since 1997, the Electronic Orange Book (EOB <http://www.fda.gov/cder/ob/default.htm>), has been available on the internet and has become the updated-every-month Orange Book.

The 25th edition and current monthly supplement are available in an electronic downloadable Portable Document Format (PDF) at the EOB home page by clicking on the Annual Edition. The PDF annual and cumulative supplements will duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The Electronic Orange Book Query (EOB) is at <http://www.fda.gov/cder/ob/default.htm>. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. Currently, In addition to monthly updates, in the public interest, the EOB is updated on a daily basis with new generic product approval information and new patent information. Current month updates are accomplished by the third week of the following month.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/cder/rxotcdpl/pdplarchive.htm>

There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/cder/orange/obreadme.htm>. The drug product text files are zipped into eobzip.exe. The files are updated concurrently with the monthly cumulative supplements. Appendix A and Appendix B text files of the annual Orange Book Edition are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.4 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2004) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2005</u>	<u>MAR 2006</u>	<u>SEP 2006</u>	<u>DEC 2006</u>
DRUG PRODUCTS LISTED	11368	11487		
SINGLE SOURCE	2428	2461		
	(21.4%)	(21.4%)		
MULTISOURCE	8851	8937		
	(77.9%)	(77.8%)		
THERAPEUTICALLY EQUIVALENT	8642	8730		
	(76.04%)	(76.0%)		
NOT THERAPEUTICALLY EQUIVALENT	209	207		
	(1.8%)	(1.8%)		
EXCEPTIONS ¹	89	89		
	(0.8%)	(0.8%)		
NEW MOLECULAR ENTITIES APPROVED	11	6		
NUMBER OF APPLICANTS	628	629		

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.5 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.

DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.
WDAG	Withdrawn. The applicant holder has notified the FDA in writing that the product is no longer being marketed resulting in the product approval being withdrawn by mutual agreement. The product will be listed in the Discontinued Section.
WDRP	Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition

PRESCRIPTION DRUG PRODUCT LIST - 26TH EDITION

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2006

1-1

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL

BUTAPAP

AB	+	MIKART	650MG;50MG	N89988	001	Oct 26, 1992	Jan	CRLD
		SEDAPAP						
		@ MAYRAND	650MG;50MG	N88944	001	Oct 17, 1985	Jan	DISC

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

	@ CLONMEL	120MG/5ML;12MG/5ML	N40098	001	Sep 20, 1996	Jan	DISC
--	-----------	--------------------	--------	-----	--------------	-----	------

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	@ ENDO PHARMS	500MG;7.5MG	N40280	001	Sep 30, 1998	Feb	DISC	
	@	650MG;7.5MG	N40280	002	Sep 30, 1998	Feb	DISC	
	@	650MG;10MG	N40280	003	Sep 30, 1998	Feb	DISC	
	@	750MG;7.5MG	N40281	002	Sep 30, 1998	Feb	DISC	
	MIKART	300MG;5MG	N40658	001	Jan 19, 2006	Jan	NEWA	
>A>	+	300MG;7.5MG	N40556	002	Mar 24, 2006	Mar	NEWA	
AA	VINTAGE PHARMS	325MG;5MG	N40655	001	Jan 19, 2006	Jan	NEWA	
AA		325MG;7.5MG	N40656	001	Jan 19, 2006	Jan	NEWA	
>D>	HY-PHEN							
>D>	AA	ASCHER	500MG;5MG	N87677	001	May 03, 1982	Mar	DISC
>A>	@	500MG;5MG	N87677	001	May 03, 1982	Mar	DISC	

ACETAZOLAMIDE

TABLET; ORAL

ACETAZOLAMIDE

>D>	AB	TARO	250MG	N40195	002	May 28, 1997	Mar	CRLD
>A>	AB	+	250MG	N40195	002	May 28, 1997	Mar	CRLD
>D>		DIAMOX						
>D>	AB	DURAMED PHARMS BARR	125MG	N08943	001		Mar	DISC
>A>	@	125MG	N08943	001			Mar	DISC
>D>	AB	+	250MG	N08943	002		Mar	DISC
>A>	@	250MG	N08943	002			Mar	DISC

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC

HYDROCORTISONE AND ACETIC ACID

AT	VINTAGE	2%;1%	N40609	001	Feb 06, 2006	Jan	NEWA
----	---------	-------	--------	-----	--------------	-----	------

ALBUTEROL

AEROSOL, METERED; INHALATION

ALBUTEROL

@ GENPHARM	0.09MG/INH	N73045	001	Aug 19, 1997	Feb	DISC
@ PLIVA	0.09MG/INH	N74072	001	Aug 01, 1996	Feb	DISC

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

>A>	AN	RXELITE	EQ 0.083% BASE	N77569	001	Apr 04, 2006	Mar	NEWA
-----	----	---------	----------------	--------	-----	--------------	-----	------

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN;
DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE
SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

INJECTABLE; INJECTION

INFUVITE ADULT

+ SANDOZ	2 IU/ML;40MG/ML;12UGM/ML;40 IU/ML;1UGM/ML;3MG/ML;120UGM/ML;8M G/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML; 660 IU/ML;0.03MG/ML	N21163 001 May 18, 2000 Jan CAHN
----------	--	----------------------------------

INJECTABLE; IV (INFUSION)

INFUVITE ADULT

+ SANDOZ	2 IU/ML;40MG/ML;12UGM/ML;40 IU/ML;1UGM/ML;3MG/ML;120UGM/ML;8M G/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML; 660 IU/ML;30UGM/ML	N21559 001 Jun 16, 2003 Jan CAHN
----------	---	----------------------------------

ALPRAZOLAM

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

AB MYLAN	0.5MG	N77391 002 Jan 26, 2006 Jan NEWA
AB	1MG	N77391 003 Jan 26, 2006 Jan NEWA
AB	2MG	N77391 004 Jan 26, 2006 Jan NEWA
AB	3MG	N77391 001 Jan 26, 2006 Jan NEWA

XANAX XR

AB PHARMACIA AND UPJOHN	0.5MG	N21434 001 Jan 17, 2003 Jan CFTG
AB	1MG	N21434 002 Jan 17, 2003 Jan CFTG
AB	2MG	N21434 003 Jan 17, 2003 Jan CFTG
AB +	3MG	N21434 004 Jan 17, 2003 Jan CFTG

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

AB AMIDE PHARM	100MG	N77659 001 Feb 23, 2006 Feb NEWA
----------------	-------	----------------------------------

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

AB PADDOCK	EQ 12% BASE	N76829 001 Feb 07, 2006 Jan NEWA
------------	-------------	----------------------------------

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

AB AM ANTIBIOTICS	250MG	N62058 001 Jan CAHN
AB	500MG	N62058 002 Jan CAHN

FOR SUSPENSION; ORAL

AMOXICILLIN

AB AM ANTIBIOTICS	125MG/5ML	N62059 001 Jan CAHN
AB	250MG/5ML	N62059 002 Jan CAHN

TABLET; ORAL

AMOXICILLIN

>A> AB HIKMA	875MG	N65255 001 Mar 29, 2006 Mar NEWA
--------------	-------	----------------------------------

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMPICILLIN TRIHYDRATE

@ AM ANTIBIOTICS

@

EQ 250MG BASE

EQ 500MG BASE

N61602 001 Jan CAHN

N61602 002 Jan CAHN

FOR SUSPENSION; ORAL

AMPICILLIN TRIHYDRATE

@ AM ANTIBIOTICS

EQ 125MG BASE/5ML

N61601 001

Jan CAHN

@

EQ 250MG BASE/5ML

N61601 002

Jan CAHN

ANIDULAFUNGIN

INJECTABLE; IV (INFUSION)

ERAXIS

+ VICURON

50MG/VIAL

N21632 001 Feb 17, 2006 Feb NEWA

ANISINDIONE

TABLET; ORAL

MIRADON

@ SCHERING

50MG

N10909 003

Jan DISC

ARTICAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION

>A> SEPTOCAINE

>A> DEPROCO

4%;EQ 0.005MG BASE/ML

N22010 001 Mar 30, 2006 Mar NEWA

>D> +

4%;EQ 0.01MG BASE/ML

N20971 001 Apr 03, 2000 Mar CPOT

>A> +

4%; EQ 0.017MG BASE/1.7ML (4%;
EQ 0.01MG BASE/ML)

N20971 001 Apr 03, 2000 Mar CPOT

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID;
NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; IV (INFUSION)

INFUVITE PEDIATRIC

+ SANDOZ

80MG/VIAL;0.02MG/VIAL;400
IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.1
4MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG
/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300
IU/VIAL;0.2MG/VIAL

N21265 001 Feb 21, 2001 Jan CAHN

INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)

+ SANDOZ

80MG/VIAL;0.02MG/VIAL;400
IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.1
4MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG
/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300
IU/VIAL;0.2MG/VIAL

N21646 001 Jan 29, 2004 Jan CAHN

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

@ ENDO PHARMS

325MG;50MG;40MG;30MG

N75351 001 Mar 05, 1999 Feb DISC

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

PERCODAN-DEMI

@ ENDO PHARMS

325MG;2.25MG;0.19MG

N07337 005

Feb DISC

BACAMPICILLIN HYDROCHLORIDE

FOR SUSPENSION; ORAL

SPECTROBID

@ PFIZER

125MG/5ML

N50556 001 Mar 23, 1982 Feb DISC

TABLET; ORAL

SPECTROBID

@ PFIZER

400MG

N50520 001

Feb DISC

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

AB	APOTEX INC	5MG	N77128 001	Mar 08, 2006	Feb	NEWA
AB		10MG	N77128 002	Mar 08, 2006	Feb	NEWA
AB		20MG	N77128 003	Mar 08, 2006	Feb	NEWA
AB		40MG	N77128 004	Mar 08, 2006	Feb	NEWA
AB	BIOKEY	5MG	N76820 001	Feb 03, 2006	Jan	NEWA
AB		10MG	N76820 002	Feb 03, 2006	Jan	NEWA
AB		20MG	N76820 003	Feb 03, 2006	Jan	NEWA
AB		40MG	N76820 004	Feb 03, 2006	Jan	NEWA

>D> BENZQUINAMIDE HYDROCHLORIDE

>D> INJECTABLE; INJECTION

>D> EMETE-CON

>D>	+	PFIZER	EQ 50MG BASE/VIAL	N16820 001		Mar	DISC
-----	---	--------	-------------------	------------	--	-----	------

>A>		@	EQ 50MG BASE/VIAL	N16820 001		Mar	DISC
-----	--	---	-------------------	------------	--	-----	------

BETAINE, ANHYDROUS

FOR SOLUTION; ORAL

CYSTADANE

+	JAZZ	1GM/SCOOPFUL	N20576 001	Oct 25, 1996	Feb	CAHN
---	------	--------------	------------	--------------	-----	------

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE

OINTMENT; TOPICAL

TACLONEX

+	LEO PHARM PRODS	0.064%;0.005%	N21852 001	Jan 09, 2006	Jan	NEWA
---	-----------------	---------------	------------	--------------	-----	------

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

BRIMONIDINE TARTRATE

AT	AKORN	0.2%	N76439 001	Mar 14, 2006	Feb	NEWA
----	-------	------	------------	--------------	-----	------

BRINZOLAMIDE

SUSPENSION/DROPS; OPHTHALMIC

AZOPT

+	ALCON	1%	N20816 001	Apr 01, 1998	Feb	CAHN
---	-------	----	------------	--------------	-----	------

BUDESONIDE

SPRAY, METERED; NASAL

RHINOCORT

>D>		ASTRAZENECA	0.032MG/INH	N20746 001	Oct 01, 1999	Mar	CRLD
-----	--	-------------	-------------	------------	--------------	-----	------

>A>	+		0.032MG/INH	N20746 001	Oct 01, 1999	Mar	CRLD
-----	---	--	-------------	------------	--------------	-----	------

>D>	+		0.064MG/INH	N20746 002	Oct 01, 1999	Mar	DISC
-----	---	--	-------------	------------	--------------	-----	------

>A>		@	0.064MG/INH	N20746 002	Oct 01, 1999	Mar	DISC
-----	--	---	-------------	------------	--------------	-----	------

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

AP	+	BEDFORD	0.25MG/ML	N74441 001	Jan 27, 1995	Feb	CRLD
----	---	---------	-----------	------------	--------------	-----	------

BUMEX

@	ROCHE	0.25MG/ML	N18226 001	Feb 28, 1983	Feb	DISC
---	-------	-----------	------------	--------------	-----	------

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE

AB	APOTEX INC	75MG	N76143 001	Jan 17, 2006	Jan	NEWA
AB		100MG	N76143 002	Jan 17, 2006	Jan	NEWA

BUSULFAN

INJECTABLE; INJECTION

BUSULFEX

+	PDL BIOPHARMA INC	6MG/ML	N20954 001	Feb 04, 1999	Jan	CAHN
---	-------------------	--------	------------	--------------	-----	------

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL

CAFERGOT

@	NOVARTIS	100MG;2MG	N09000 002		Feb	DISC
---	----------	-----------	------------	--	-----	------

MIGERGOT

+	G AND W LABS	100MG;2MG	N86557 001	Oct 04, 1983	Feb	CRLD
---	--------------	-----------	------------	--------------	-----	------

CALCIPOTRIENE

CREAM; TOPICAL

DOVONEX

+	LEO PHARM	0.005%	N20554 001	Jul 22, 1996	Feb	CAHN
---	-----------	--------	------------	--------------	-----	------

OINTMENT; TOPICAL

DOVONEX

+	LEO PHARM	0.005%	N20273 001	Dec 29, 1993	Feb	CAHN
---	-----------	--------	------------	--------------	-----	------

SOLUTION; TOPICAL

DOVONEX

+	LEO PHARM	0.005%	N20611 001	Mar 03, 1997	Feb	CAHN
---	-----------	--------	------------	--------------	-----	------

CALCITONIN, SALMON

INJECTABLE; INJECTION

MIACALCIN

+	NOVARTIS	200 IU/ML	N17808 002	Mar 29, 1991	Jan	CTEC
---	----------	-----------	------------	--------------	-----	------

CALCITRIOL

CAPSULE; ORAL

CALCITRIOL

>A>	AB	ROXANE	0.25UGM	N76917 001	Mar 27, 2006	Mar	NEWA
-----	----	--------	---------	------------	--------------	-----	------

INJECTABLE; INJECTION

CALCITRIOL

AP	GENIX THERAP	0.001MG/ML	N77102 001	Feb 08, 2006	Jan	NEWA
----	--------------	------------	------------	--------------	-----	------

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

@	CLONMEL HLTHCARE	12.5MG	N74423 001	Feb 13, 1996	Jan	DISC
---	------------------	--------	------------	--------------	-----	------

@		25MG	N74423 002	Feb 13, 1996	Jan	DISC
---	--	------	------------	--------------	-----	------

@		50MG	N74423 003	Feb 13, 1996	Jan	DISC
---	--	------	------------	--------------	-----	------

@		100MG	N74423 004	Feb 13, 1996	Jan	DISC
---	--	-------	------------	--------------	-----	------

@	ENDO LABS	12.5MG	N74418 001	Feb 13, 1996	Feb	DISC
---	-----------	--------	------------	--------------	-----	------

@		25MG	N74418 002	Feb 13, 1996	Feb	DISC
---	--	------	------------	--------------	-----	------

@		50MG	N74418 003	Feb 13, 1996	Feb	DISC
---	--	------	------------	--------------	-----	------

@		100MG	N74418 004	Feb 13, 1996	Feb	DISC
---	--	-------	------------	--------------	-----	------

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

@ ENDO LABS 25MG;15MG
 @ 25MG;25MG
 @ 50MG;15MG
 @ 50MG;25MG

N74788 001 Dec 29, 1997 Feb DISC
 N74788 002 Dec 29, 1997 Feb DISC
 N74788 004 Dec 29, 1997 Feb DISC
 N74788 003 Dec 29, 1997 Feb DISC

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

AP WATSON LABS 50MG/VIAL
 AP 150MG/VIAL
 AP 450MG/VIAL

N77383 001 Jan 27, 2006 Jan NEWA
 N77383 002 Jan 27, 2006 Jan NEWA
 N77383 003 Jan 27, 2006 Jan NEWA

INJECTABLE; IV (INFUSION)

CARBOPLATIN

@ AM PHARM EQ 50MG/5ML (10MG/ML)
 AP EQ 50MG/5ML (10MG/ML)
 @ EQ 150MG/15ML (10MG/ML)
 AP EQ 150MG/15ML (10MG/ML)
 AP EQ 450MG/45ML (10MG/ML)
 AP EQ 600MG/60ML (10MG/ML)
 AP BEDFORD LABS EQ 600MG/60ML (10MG/ML)

N77247 001 Oct 21, 2004 Feb DISC
 N77266 001 Feb 15, 2006 Jan NEWA
 N77247 002 Oct 21, 2004 Feb DISC
 N77266 002 Feb 15, 2006 Jan NEWA
 N77266 003 Feb 15, 2006 Jan NEWA
 N77266 004 Feb 15, 2006 Jan NEWA
 N77244 004 Jan 20, 2006 Jan NEWA

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

CEFADROXIL

>D> AB IVAX PHARMS EQ 500MG BASE
 >A> AB + EQ 500MG BASE
 AB TEVA PHARMS EQ 500MG BASE
 AB WESTWARD EQ 500MG BASE

N62766 001 Mar 03, 1987 Mar CRLD
 N62766 001 Mar 03, 1987 Mar CRLD
 N65282 001 Jan 20, 2006 Jan NEWA
 N65311 001 Feb 07, 2006 Jan NEWA

DURICEF

@ WARNER CHILCOTT EQ 500MG BASE

N50512 001 Jan DISC

FOR SUSPENSION; ORAL

CEFADROXIL

RANBAXY EQ 125MG BASE/5ML
 AB TEVA PHARMS EQ 250MG BASE/5ML
 AB EQ 500MG BASE/5ML

N65115 001 Mar 26, 2003 Feb CTEC
 N65278 001 Jan 20, 2006 Jan NEWA
 N65278 002 Jan 20, 2006 Jan NEWA

DURICEF

@ WARNER CHILCOTT EQ 125MG BASE/5ML

N50527 002 Feb DISC

TABLET; ORAL

CEFADROXIL

>A> AB HIKMA EQ 1GM BASE
 AB + IVAX PHARMS EQ 1GM BASE

N65260 001 Mar 30, 2006 Mar NEWA
 N62774 001 Apr 08, 1987 Feb CRLD

DURICEF

@ WARNER CHILCOTT EQ 1GM BASE

N50528 001 Jan DISC

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

AP ORCHID HLTHCARE EQ 1GM BASE/VIAL
 AP EQ 2GM BASE/VIAL
 AP EQ 10GM BASE/VIAL

N65313 001 Jan 23, 2006 Jan NEWA
 N65313 002 Jan 23, 2006 Jan NEWA
 N65312 001 Feb 13, 2006 Jan NEWA

CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER

AP B BRAUN EQ 1GM BASE/VIAL

N65214 001 Mar 10, 2006 Feb NEWA

INJECTABLE; INJECTION

CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER

AP	B BRAUN	EQ 2GM BASE/VIAL	N65214 002	Mar 10, 2006	Feb	NEWA
----	---------	------------------	------------	--------------	-----	------

CEFTRIAZONE SODIUM

INJECTABLE; IM-IV

CEFTRIAZONE

AP	AM PHARM PARTNERS	EQ 250MG BASE/VIAL	N65245 001	Feb 15, 2006	Jan	NEWA
AP		EQ 500MG BASE/VIAL	N65245 002	Feb 15, 2006	Jan	NEWA
AP		EQ 1GM BASE/VIAL	N65245 003	Feb 15, 2006	Jan	NEWA
AP		EQ 2GM BASE/VIAL	N65245 004	Feb 15, 2006	Jan	NEWA

INJECTABLE; INJECTION

CEFTRIAZONE

AP	AM PHARM	EQ 10GM BASE/VIAL	N65252 001	Feb 15, 2006	Jan	NEWA
----	----------	-------------------	------------	--------------	-----	------

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

>A>	AB	AUROBINDO PHARMA LTD	EQ 125MG BASE	N65308 001	Mar 29, 2006	Mar	NEWA
>A>	AB		EQ 250MG BASE	N65308 002	Mar 29, 2006	Mar	NEWA
>A>	AB		EQ 500MG BASE	N65308 003	Mar 29, 2006	Mar	NEWA

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

AB	HIKMA	EQ 250MG BASE	N65215 001	Jan 24, 2006	Jan	NEWA
AB		EQ 500MG BASE	N65215 002	Jan 24, 2006	Jan	NEWA

CEPHRADINE

CAPSULE; ORAL

ANSPOR

>D>	AB	GLAXOSMITHKLINE	250MG	N61859 001		Mar	DISC
>A>		@	250MG	N61859 001		Mar	DISC
>D>	AB		500MG	N61859 002		Mar	DISC
>A>		@	500MG	N61859 002		Mar	DISC

CICLOPIROX

CREAM; TOPICAL

CICLOPIROX

>A>	AB	PERRIGO	0.77%	N77364 001	Mar 03, 2006	Mar	CAHN
>D>	AB	PERRIGO NEW YORK	0.77%	N77364 001	Mar 03, 2006	Mar	CAHN
	AB		0.77%	N77364 001	Mar 03, 2006	Feb	NEWA

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

>A>	AB	MUTUAL PHARM	50MG	N77208 002	Mar 29, 2006	Mar	NEWA
>A>	AB		100MG	N77208 001	Mar 29, 2006	Mar	NEWA

CIMETIDINE

TABLET; ORAL

CIMETIDINE

@ ENDO PHARMS

@

@

200MG

300MG

400MG

N74281 001	May 17, 1994	Feb	DISC
N74281 002	May 17, 1994	Feb	DISC
N74281 003	May 17, 1994	Feb	DISC

TABLET; ORAL

CIMETIDINE

@ ENDO PHARMS

800MG

N74329 001 May 17, 1994 Feb DISC

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HYDROCHLORIDE

@ ENDO PHARMS

EQ 300MG BASE/2ML

N74005 001 Aug 31, 1994 Feb DISC

SOLUTION; ORAL

CIMETIDINE HYDROCHLORIDE

@ ENDO PHARMS

EQ 300MG BASE/5ML

N74251 001 Dec 22, 1994 Feb DISC

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

>A> AB

TARO

EQ 10MG BASE

N77278 001 Mar 22, 2006 Mar NEWA

>A> AB

EQ 20MG BASE

N77278 002 Mar 22, 2006 Mar NEWA

>A> AB

EQ 40MG BASE

N77278 003 Mar 22, 2006 Mar NEWA

>A> AB

TEVA PHARMS

EQ 10MG BASE

N77213 001 Mar 31, 2006 Mar NEWA

>A> AB

EQ 20MG BASE

N77213 002 Mar 31, 2006 Mar NEWA

>A> AB

EQ 40MG BASE

N77213 003 Mar 31, 2006 Mar NEWA

CLINDAMYCIN PHOSPHATE

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

AT

ALTANA

EQ 1% BASE

N65254 001 Feb 14, 2006 Jan NEWA

CLOBETASOL PROPIONATE

SPRAY; TOPICAL

CLOBEX

+ GALDERMA LABS LP

0.05%

N21835 001 Oct 27, 2005 Feb CAHN

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

AB

APOTEX

EQ 75MG BASE

N76274 001 Jan 20, 2006 Jan NEWA

PLAVIX

AB

+ SANOFI SYNTHELABO

EQ 75MG BASE

N20839 001 Nov 17, 1997 Jan CFTG

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETH VC W/ CODEINE

+ ALPHARMA US PHARMS

10MG/5ML;5MG/5ML;6.25MG/5ML

N88764 001 Oct 31, 1984 Jan CTEC

PROMETHAZINE VC W/ CODEINE

@ MORTON GROVE

10MG/5ML;5MG/5ML;6.25MG/5ML

N88896 001 Jan 04, 1985 Jan DISC

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE WITH CODEINE SYRUP

AA

VINTAGE

10MG/5ML;6.25MG/5ML

N40650 001 Jan 31, 2006 Jan NEWA

CROMOLYN SODIUM

SOLUTION, CONCENTRATE; ORAL

GASTROCROM

+ AZUR PHARMA

100MG/5ML

N20479 001 Feb 29, 1996 Feb CAHN

CYANOCOBALAMIN

>D>	GEL, METERED; NASAL						
>D>	NASCOBAL						
>D>	+ QOL MEDCL	0.5MG/INH	N19722	001	Nov 05, 1996	Mar	DISC
>A>	@	0.5MG/INH	N19722	001	Nov 05, 1996	Mar	DISC

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB	AMIDE PHARM	5MG	N77291	001	Feb 03, 2006	Jan	NEWA	
>A>	AB	MUTUAL PHARM	5MG	N73541	002	Apr 06, 2006	Mar	NEWA
AB	MYLAN	5MG	N73144	002	Feb 03, 2006	Jan	NEWA	
AB	SANDOZ	5MG	N72854	002	Feb 03, 2006	Jan	NEWA	
AB	WATSON LABS	5MG	N71611	002	Feb 03, 2006	Jan	NEWA	
		7.5MG	N71611	003	Feb 03, 2006	Jan	NEWA	
	FLEXERIL							
AB	MCNEIL CONS SPECLT	5MG	N17821	001		Jan	CFTG	

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION

DEFEROXAMINE MESYLATE

>A>	AP	SICOR PHARMS	500MG/VIAL	N76806	001	Mar 31, 2006	Mar	NEWA
>A>	AP		2GM/VIAL	N76806	002	Mar 31, 2006	Mar	NEWA

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DECLOMYCIN

>A>	@	GLADES PHARMS LLC	75MG	N50261	001		Mar	CAHN
>A>	AB		150MG	N50261	002		Mar	CAHN
>A>	AB	+	300MG	N50261	003		Mar	CAHN
>D>	@	PROTEIN DESIGN LABS	75MG	N50261	001		Mar	CAHN
	@		75MG	N50261	001		Feb	CAHN
>D>	AB		150MG	N50261	002		Mar	CAHN
	AB		150MG	N50261	002		Feb	CAHN
>D>	AB	+	300MG	N50261	003		Mar	CAHN
	AB	+	300MG	N50261	003		Feb	CAHN

DES Loratadine; Pseudoephedrine Sulfate

TABLET, EXTENDED RELEASE; ORAL

CLARINEX-D 12 HOUR

+	SCHERING	2.5MG;120MG	N21313	001	Feb 01, 2006	Feb	NEWA
---	----------	-------------	--------	-----	--------------	-----	------

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

DESMOPRESSIN ACETATE

@ BEDFORD 0.004MG/ML

N74575 001 Feb 18, 2000 Jan DISC

DESMOPRESSIN ACETATE PRESERVATIVE FREE

@ BEDFORD 0.004MG/ML

N74574 001 Feb 18, 2000 Jan DISC

TABLET; ORAL

DESMOPRESSIN ACETATE

AB	APOTEX	0.1MG	N77414	001	Mar 07, 2006	Feb	NEWA
AB		0.2MG	N77414	002	Mar 07, 2006	Feb	NEWA
AB	TEVA PHARMS	0.1MG	N77122	001	Jan 25, 2006	Jan	NEWA
AB		0.2MG	N77122	002	Jan 25, 2006	Jan	NEWA

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

MIRCETTE

AB	+	DURAMED	0.15MG,N/A;0.02MG,0.01MG	N20713	001	Apr 22, 1998	Feb	CAHN
AB	+		0.15MG,N/A;0.02MG,0.01MG	N20713	001	Apr 22, 1998	Feb	CAHN

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE

>A>	AP	BAXTER HLTHCARE	EQ 10MG PHOSPHATE/ML	N87702	001	Sep 07, 1982	Mar	CAHN
>D>	AP	ELKINS SINN	EQ 10MG PHOSPHATE/ML	N87702	001	Sep 07, 1982	Mar	CAHN

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

@ ENDO PHARMS 5MG

N40299 001 May 13, 1999 Feb DISC

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE DM

AA		VINTAGE	15MG/5ML;6.25MG/5ML	N40649	001	Feb 14, 2006	Jan	NEWA
----	--	---------	---------------------	--------	-----	--------------	-----	------

DIAZEPAM

TABLET; ORAL

DIAZEPAM

>A>	AB	VINTAGE PHARMS	2MG	N77749	001	Mar 31, 2006	Mar	NEWA
>A>	AB		5MG	N77749	002	Mar 31, 2006	Mar	NEWA
>A>	AB		10MG	N77749	003	Mar 31, 2006	Mar	NEWA

DIFLORASONE DIACETATE

CREAM; TOPICAL

DIFLORASONE DIACETATE

BX	+	ALTANA	0.05%	N76263	001	Dec 20, 2002	Jan	CRLD
----	---	--------	-------	--------	-----	--------------	-----	------

FLORONE

@ PHARMACIA AND UPJOHN 0.05%

N17741 001 Jan DISC

FLORONE E

@ PHARMACIA AND UPJOHN 0.05%

N19259 001 Aug 28, 1985 Jan DISC

OINTMENT; TOPICAL

DIFLORASONE DIACETATE

AB	+	TARO	0.05%	N75331	001	May 14, 1999	Jan	CRLD
----	---	------	-------	--------	-----	--------------	-----	------

FLORONE

@ PHARMACIA AND UPJOHN 0.05%

N17994 001 Jan DISC

PSORCON

@ PHARMACIA AND UPJOHN 0.05%

N19260 001 Aug 28, 1985 Jan DISC

DIGOXIN

INJECTABLE; INJECTION

DIGOXIN

AP		SANDOZ	0.25MG/ML	N40481	001	Aug 21, 2003	Jan	CAHN
----	--	--------	-----------	--------	-----	--------------	-----	------

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILTAC

AB4		APOTEX INC	120MG	N76395	001	Feb 01, 2006	Jan	NEWA
-----	--	------------	-------	--------	-----	--------------	-----	------

CAPSULE, EXTENDED RELEASE; ORAL

DILTZAC

AB4	APOTEX INC	180MG	N76395 002	Feb 01, 2006	Jan	NEWA
AB4		240MG	N76395 003	Feb 01, 2006	Jan	NEWA
AB4		300MG	N76395 004	Feb 01, 2006	Jan	NEWA
AB4		360MG	N76395 005	Feb 01, 2006	Jan	NEWA

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATE

@	IVAX PHARMS	EQ 100MG BASE	N70186 001	Nov 18, 1985	Jan	DISC
@		EQ 150MG BASE	N70187 001	Nov 18, 1985	Jan	DISC
@	SANDOZ	EQ 100MG BASE	N70470 001	Dec 10, 1985	Jan	DISC
@		EQ 150MG BASE	N70471 001	Dec 10, 1985	Jan	DISC

>A> DOLASETRON MESYLATE

>A> INJECTABLE; INJECTION

>A> ANZEMET

>A>	+	SANOFI AVENTIS US	EQ 12.5MG BASE/0.625ML (EQ 20MG BASE/ML)	N20624 002	Sep 11, 1997	Mar	CAIN
>A>	+		EQ 100MG BASE/5ML (EQ 20MG BASE/ML)	N20624 001	Sep 11, 1997	Mar	CAIN
>A>	+		EQ 500MG BASE/25ML (EQ 20MG BASE/ML)	N20624 003	Dec 11, 2001	Mar	CAIN

>A> TABLET; ORAL

>A> ANZEMET

>A>		SANOFI AVENTIS US	EQ 50MG BASE	N20623 001	Sep 11, 1997	Mar	CAIN
>A>	+		EQ 100MG BASE	N20623 002	Sep 11, 1997	Mar	CAIN

>D> DOLASETRON MESYLATE MONOHYDRATE

>D> INJECTABLE; INJECTION

>D> ANZEMET

>D>		SANOFI AVENTIS US	EQ 12.5MG BASE/0.625ML	N20624 002	Sep 11, 1997	Mar	CAIN
>D>	+		EQ 100MG BASE/5ML	N20624 001	Sep 11, 1997	Mar	CAIN
>D>	+		EQ 500MG BASE/25ML	N20624 003	Dec 11, 2001	Mar	CAIN

>D> TABLET; ORAL

>D> ANZEMET

>D>		SANOFI AVENTIS US	EQ 50MG BASE	N20623 001	Sep 11, 1997	Mar	CAIN
>D>	+		EQ 100MG BASE	N20623 002	Sep 11, 1997	Mar	CAIN

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

>D>	AB	PAR PHARM	EQ 75MG BASE	N65055 004	Apr 18, 2005	Mar	DISC
>A>		@	EQ 75MG BASE	N65055 004	Apr 18, 2005	Mar	DISC
>D>			EQ 150MG BASE	N65055 003	Jul 15, 2005	Mar	DISC
>A>		@	EQ 150MG BASE	N65055 003	Jul 15, 2005	Mar	DISC
>D>	AB	RANBAXY	EQ 75MG BASE	N65053 003	Sep 10, 2003	Mar	CTEC
>A>			EQ 75MG BASE	N65053 003	Sep 10, 2003	Mar	CTEC

TABLET; ORAL

DOXYCYCLINE

>D>		@ PAR PHARM	EQ 75MG BASE	N65070 003	Dec 30, 2002	Mar	CMFD
>A>			EQ 75MG BASE	N65070 003	Dec 30, 2002	Mar	CMFD

DOXYCYCLINE HYCLATE

TABLET; ORAL

DOXYCYCLINE HYCLATE

AB	PAR PHARM	EQ 20MG BASE	N65287 001	Feb 28, 2006	Feb	NEWA
----	-----------	--------------	------------	--------------	-----	------

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL

YAZ

>A>						
>A>	+	BERLEX LABS	3MG;0.02MG	N21676 001	Mar 16, 2006	Mar NEWA

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

XYLOCAINE W/ EPINEPHRINE

>D>		DENTSPLY PHARM	0.02MG/ML;2%	N21381 002		Mar CRLD
>A>	+		0.02MG/ML;2%	N21381 002		Mar CRLD

ERYTHROMYCIN

SOLUTION; TOPICAL

A/T/S

AT	TARO PHARMS NORTH	2%	N62405 001	Nov 18, 1982	Feb	CAHN
----	-------------------	----	------------	--------------	-----	------

ESTRADIOL

GEL; TOPICAL

ESTROGEL

@ ASCEND

0.06%

N21166 001	Feb 09, 2004	Jan	CAHN
------------	--------------	-----	------

GEL, METERED; TOPICAL

ESTROGEL

+ ASCEND

0.06%

N21166 002	Feb 09, 2004	Jan	CAHN
------------	--------------	-----	------

ESTRADIOL HEMIHYDRATE

EMULSION; TOPICAL

ESTRASORB

+ ESPRIT PHARMA

0.25%

N21371 001	Oct 09, 2003	Feb	CAHN
------------	--------------	-----	------

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET; ORAL

ENJUVIA

>D>	@	DURAMED	0.3MG	N21443 001	Dec 20, 2004	Mar	CMFD
>A>			0.3MG	N21443 001	Dec 20, 2004	Mar	CMFD
>D>	@		0.45MG	N21443 002	Dec 20, 2004	Mar	CMFD
>A>			0.45MG	N21443 002	Dec 20, 2004	Mar	CMFD
>D>	@		0.625MG	N21443 003	May 10, 2004	Mar	CMFD
>A>			0.625MG	N21443 003	May 10, 2004	Mar	CMFD
>D>	@		1.25MG	N21443 004	May 10, 2004	Mar	CMFD
>A>	+		1.25MG	N21443 004	May 10, 2004	Mar	CMFD

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

BALZIVA-21

>D>	+	BARR	0.035MG;0.4MG	N76198 001	Apr 22, 2004	Mar	CRLD
>A>			0.035MG;0.4MG	N76198 001	Apr 22, 2004	Mar	CRLD

TABLET; ORAL-28

OVCON-35

>D>	AB	WARNER CHILCOTT	0.035MG;0.4MG	N17716 001		Mar	CRLD
-----	----	-----------------	---------------	------------	--	-----	------

TABLET; ORAL-28									
OVCON-35									
>A>	AB	+	WARNER CHILCOTT	0.035MG;0.4MG		N17716	001	Mar	CRLD
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE</u>									
TABLET; ORAL									
LOESTRIN 24 FE									
		+	WARNER CHILCOTT	0.02MG;1MG		N21871	001	Feb 17, 2006	Feb NEWA
<u>ETODOLAC</u>									
CAPSULE; ORAL									
ETODOLAC									
			@ ENDO PHARMS	200MG		N74842	001	Jul 17, 1997	Feb DISC
			@	300MG		N74842	002	Jul 17, 1997	Feb DISC
>D>	AB		TARO	300MG		N75078	002	Apr 30, 1998	Mar CRLD
>A>	AB	+		300MG		N75078	002	Apr 30, 1998	Mar CRLD
>D>			LODINE						
>D>	AB	+	WYETH PHARMS INC	300MG		N18922	003	Jan 31, 1991	Mar DISC
>A>			@	300MG		N18922	003	Jan 31, 1991	Mar DISC
TABLET; ORAL									
ETODOLAC									
			@ ENDO PHARMS	400MG		N74841	001	Jun 27, 1997	Feb DISC
<u>FENOFIBRATE</u>									
CAPSULE; ORAL									
LIPOFEN									
			CIPHER	50MG		N21612	001	Jan 11, 2006	Jan NEWA
				100MG		N21612	002	Jan 11, 2006	Jan NEWA
			+	150MG		N21612	003	Jan 11, 2006	Jan NEWA
TABLET; ORAL									
FENOFIBRATE									
AB	+		TEVA	160MG		N76433	002	May 13, 2005	Jan CRLD
			TRICOR						
			@ ABBOTT	54MG		N21203	001	Sep 04, 2001	Jan DISC
			@	160MG		N21203	003	Sep 04, 2001	Jan DISC
<u>FENOLDOPAM MESYLATE</u>									
INJECTABLE; INJECTION									
FENOLDOPAM MESYLATE									
AP			SANDOZ	EQ 10MG BASE/ML		N77155	001	Feb 15, 2005	Jan CAHN
<u>FENOPROFEN CALCIUM</u>									
TABLET; ORAL									
FENOPROFEN CALCIUM									
			@ CLONMEL HLTHCARE	EQ 600MG BASE		N72326	001	Aug 17, 1988	Jan DISC
<u>FENTANYL CITRATE</u>									
TROCHE/LOZENGE; TRANSMUCOSAL									
>D>			ACTIQ						
>D>			CEPHALON	EQ 0.2MG BASE		N20747	001	Nov 04, 1998	Mar CTNA
>D>		+		EQ 0.4MG BASE		N20747	002	Nov 04, 1998	Mar CTNA
>D>				EQ 0.6MG BASE		N20747	003	Nov 04, 1998	Mar CTNA
>D>				EQ 0.8MG BASE		N20747	004	Nov 04, 1998	Mar CTNA
>D>				EQ 1.2MG BASE		N20747	005	Nov 04, 1998	Mar CTNA
>D>				EQ 1.6MG BASE		N20747	006	Nov 04, 1998	Mar CTNA

TROCHE/LOZENGE; TRANSMUCOSAL

>A> ACTIQ (SUGAR-FREE)

>A>	CEPHALON	EQ 0.2MG BASE	N20747 001	Nov 04, 1998	Mar	CTNA
>A>	+	EQ 0.4MG BASE	N20747 002	Nov 04, 1998	Mar	CTNA
>A>		EQ 0.6MG BASE	N20747 003	Nov 04, 1998	Mar	CTNA
>A>		EQ 0.8MG BASE	N20747 004	Nov 04, 1998	Mar	CTNA
>A>		EQ 1.2MG BASE	N20747 005	Nov 04, 1998	Mar	CTNA
>A>		EQ 1.6MG BASE	N20747 006	Nov 04, 1998	Mar	CTNA

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL

FEXOFENADINE HYDROCHLORIDE

>A>	AB	DR REDDYS LABS LTD	30MG	N76502 001	Apr 11, 2006	Mar	NEWA
>A>	AB		60MG	N76502 002	Apr 11, 2006	Mar	NEWA
>A>	AB		180MG	N76502 003	Apr 11, 2006	Mar	NEWA

FLUCONAZOLE

TABLET; ORAL

FLUCONAZOLE

AB	GLENMARK PHARMA	50MG	N77253 001	Jan 25, 2006	Jan	NEWA
AB		100MG	N77253 002	Jan 25, 2006	Jan	NEWA
AB		150MG	N77253 003	Jan 25, 2006	Jan	NEWA
AB		200MG	N77253 004	Jan 25, 2006	Jan	NEWA

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

AP	SANDOZ	1MG/10ML (0.1MG/ML)	N77071 002	May 03, 2005	Jan	CAHN
AP		0.5MG/5ML (0.1MG/ML)	N77071 001	May 03, 2005	Jan	CAHN

FLUNISOLIDE

AEROSOL, METERED; INHALATION

AEROSPAN HFA

+	FOREST LABS	EQ 78UGM BASE/INH	N21247 001	Jan 27, 2006	Jan	NEWA
---	-------------	-------------------	------------	--------------	-----	------

FLUORESCEIN SODIUM

>A> INJECTABLE; INTRAVENOUS

>A> FLUORESCITE

>A>	+	ALCON RES	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N21980 001	Mar 28, 2006	Mar	NEWA
-----	---	-----------	--------------------------------------	------------	--------------	-----	------

FLUOROURACIL

INJECTABLE; INJECTION

ADRUCIL

>D>	AP	SICOR PHARMS	50MG/ML	N40023 001	Oct 18, 1991	Mar	CRLD
>A>	AP	+	50MG/ML	N40023 001	Oct 18, 1991	Mar	CRLD
		FLUOROURACIL					
>D>	AP	AM PHARM	50MG/ML	N40291 001	Mar 24, 1999	Mar	CRLD
>D>	AP	AM PHARM PARTNERS	50MG/ML	N40278 001	Sep 30, 1998	Mar	CRLD
>A>	AP	+	50MG/ML	N40278 001	Sep 30, 1998	Mar	CRLD
>D>	AP		50MG/ML	N40279 001	Sep 30, 1998	Mar	CRLD
>A>	AP	+	50MG/ML	N40279 001	Sep 30, 1998	Mar	CRLD
>A>	AP	+	50MG/ML	N40291 001	Mar 24, 1999	Mar	CRLD
>D>	AP		50MG/ML	N40379 001	Nov 15, 2000	Mar	CRLD
>A>	AP	+	50MG/ML	N40379 001	Nov 15, 2000	Mar	CRLD
>D>	AP	BEDFORD	50MG/ML	N89508 001	Jan 26, 1988	Mar	CRLD

INJECTABLE; INJECTION

FLUOROURACIL

>A>	AP	+	BEDFORD	50MG/ML	N89508	001	Jan 26, 1988	Mar	CRLD
>D>	AP		SICOR PHARMS	50MG/ML	N40333	001	Jan 27, 2000	Mar	CRLD
>A>	AP	+		50MG/ML	N40333	001	Jan 27, 2000	Mar	CRLD
>D>	AP			50MG/ML	N40334	001	Feb 25, 2000	Mar	CRLD
>A>	AP	+		50MG/ML	N40334	001	Feb 25, 2000	Mar	CRLD
>D>	AP		STERIS	50MG/ML	N87792	001	Oct 13, 1982	Mar	CRLD
>A>	AP	+		50MG/ML	N87792	001	Oct 13, 1982	Mar	CRLD

FLUTICASONE PROPIONATE

OINTMENT; TOPICAL

FLUTICASONE PROPIONATE

AB			G AND W LABS	0.005%	N77168	001	Mar 03, 2006	Feb	NEWA
			SPRAY, METERED; NASAL						
			FLONASE						
AB	+		GLAXOSMITHKLINE	0.05MG/SPRAY	N20121	001	Oct 19, 1994	Feb	CFTG
			FLUTICASONE PROPIONATE						
AB			ROXANE	0.05MG/SPRAY	N76504	001	Feb 22, 2006	Feb	NEWA

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

AB			CARACO	25MG	N75900	001	Feb 23, 2006	Feb	NEWA
AB				50MG	N75900	002	Feb 23, 2006	Feb	NEWA
AB				100MG	N75900	003	Feb 23, 2006	Feb	NEWA
>A>	AB		LEINER	25MG	N75888	001	Nov 29, 2000	Mar	CAHN
>A>	AB			50MG	N75888	002	Nov 29, 2000	Mar	CAHN
>A>	AB	+		100MG	N75888	003	Nov 29, 2000	Mar	CAHN
>D>	AB		SANDOZ	25MG	N75888	001	Nov 29, 2000	Mar	CAHN
>D>	AB			50MG	N75888	002	Nov 29, 2000	Mar	CAHN
>D>	AB	+		100MG	N75888	003	Nov 29, 2000	Mar	CAHN

FOSCARNET SODIUM

INJECTABLE; INJECTION

FOSCARNET SODIUM

AP			HOSPIRA	2.4GM/100ML	N77174	001	May 31, 2005	Feb	CAHN
----	--	--	---------	-------------	--------	-----	--------------	-----	------

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

AB			SANDOZ	100MG	N75428	001	Jan 24, 2006	Jan	NEWA
AB				300MG	N75428	002	Jan 24, 2006	Jan	NEWA
AB				400MG	N75428	003	Jan 24, 2006	Jan	NEWA

TABLET; ORAL

GABAPENTIN

AB			SANDOZ	600MG	N76120	001	Jan 27, 2006	Jan	NEWA
AB				800MG	N76120	002	Jan 27, 2006	Jan	NEWA

GADOVERSETAMIDE

INJECTABLE; INJECTION

OPTIMARK

+			MALLINCKRODT	1654.5MG/5ML (330.9MG/ML)	N20937	001	Dec 08, 1999	Jan	CPOT
+				3309MG/10ML (330.9MG/ML)	N20937	002	Dec 08, 1999	Jan	NEWA
+				4963.5MG/15ML (330.9MG/ML)	N20937	003	Dec 08, 1999	Jan	NEWA

INJECTABLE; INJECTION

OPTIMARK

+	MALLINCKRODT	6618MG/20ML (330.9MG/ML)	N20937	004	Dec 08,	1999	Jan	NEWA
+		16.545GM/50ML (330.9MG/ML)	N20975	001	Dec 08,	1999	Jan	CPOT

OPTIMARK IN PLASTIC CONTAINER

+	MALLINCKRODT	1654.5MG/5ML (330.9MG/ML)	N20976	001	Dec 08,	1999	Jan	CPOT
+		3309MG/10ML (330.9MG/ML)	N20976	002	Dec 08,	1999	Jan	NEWA
+		4963.5MG/15ML (330.9MG/ML)	N20976	003	Dec 08,	1999	Jan	NEWA
+		6618MG/20ML (330.9MG/ML)	N20976	004	Dec 08,	1999	Jan	NEWA

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

AB	COBALT	1MG	N77280	001	Feb 03,	2006	Jan	NEWA
AB		2MG	N77280	002	Feb 03,	2006	Jan	NEWA
AB		4MG	N77280	003	Feb 03,	2006	Jan	NEWA
AB	GENPHARM	1MG	N77486	001	Feb 10,	2006	Jan	NEWA
AB		2MG	N77486	002	Feb 10,	2006	Jan	NEWA
AB		4MG	N77486	003	Feb 10,	2006	Jan	NEWA

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

@	ENDO PHARMS	5MG	N74378	001	Nov 28,	1994	Feb	DISC
@		10MG	N74378	002	Nov 28,	1994	Feb	DISC

TABLET, EXTENDED RELEASE; ORAL

GLIPIZIDE

>A>	AB	WATSON LABS	2.5MG	N76467	003	Mar 27,	2006	Mar	NEWA
		GLUCOTROL XL							
>D>		PFIZER	2.5MG	N20329	003	Aug 10,	1999	Mar	CFTG
>A>	AB		2.5MG	N20329	003	Aug 10,	1999	Mar	CFTG

GLYBURIDE

TABLET; ORAL

DIABETA

BX	+	SANOFI AVENTIS US	5MG	N17532	003	May 01,	1984	Feb	CRLD
----	---	-------------------	-----	--------	-----	---------	------	-----	------

HALOBETASOL PROPIONATE

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

>D>	AB	AGIS INDS	0.05%	N76872	001	Dec 16,	2004	Mar	CAHN
>A>	AB	PERRIGO	0.05%	N76872	001	Dec 16,	2004	Mar	CAHN

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

AO	SANDOZ	EQ 50MG BASE/ML	N76463	001	Jun 24,	2005	Jan	CAHN
AO		EQ 100MG BASE/ML	N76463	002	Jun 24,	2005	Jan	CAHN

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALOPERIDOL

AP	SANDOZ	EQ 5MG BASE/ML	N76464	001	Sep 29,	2004	Jan	CAHN
----	--------	----------------	--------	-----	---------	------	-----	------

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

APRESOLINE

@ NOVARTIS

10MG

N08303 004

Feb DISC

@

25MG

N08303 001

Feb DISC

@

50MG

N08303 002

Feb DISC

@

100MG

N08303 005

Feb DISC

HYDRALAZINE HYDROCHLORIDE

AA + PLIVA

10MG

N89097 001 Dec 18, 1985 Feb CRLD

AA +

25MG

N88467 001 May 01, 1984 Feb CRLD

AA +

50MG

N88468 001 May 01, 1984 Feb CRLD

AA +

100MG

N89098 001 Dec 18, 1985 Feb CRLD

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

AB AUROBINDO

12.5MG;10MG

N77606 001 Mar 14, 2006 Feb NEWA

AB

12.5MG;20MG

N77606 002 Mar 14, 2006 Feb NEWA

AB

25MG;20MG

N77606 003 Mar 14, 2006 Feb NEWA

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-HYDROCORT

>A> AP

HOSPIRA

EQ 100MG BASE/VIAL

N40666 001 Apr 06, 2006 Mar NEWA

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

>D> AB

BARR

EQ 100MG HCL

N88488 001 Jun 15, 1984 Mar CTEC

>A>

EQ 100MG HCL

N88488 001 Jun 15, 1984 Mar CTEC

VISTARIL

>D> AB

PFIZER

EQ 100MG HCL

N11459 006 Mar DISC

>A>

@

EQ 100MG HCL

N11459 006 Mar DISC

IBANDRONATE SODIUM

INJECTABLE; INTRAVENOUS

BONIVA

+ ROCHE

EQ 3MG BASE/3ML

N21858 001 Jan 06, 2006 Jan NEWA

INSULIN GLULISINE RECOMBINANT

INJECTABLE; SUBCUTANEOUS

APIDRA

>D>

@ SANOFI AVENTIS US

1000 UNITS/10ML (100 UNITS/ML)

N21629 001 Apr 16, 2004 Mar CMFD

>A>

+

1000 UNITS/10ML (100 UNITS/ML)

N21629 001 Apr 16, 2004 Mar CMFD

>D>

@

300 UNITS/3ML (100 UNITS/ML)

N21629 002 Dec 20, 2005 Mar CMFD

>A>

+

300 UNITS/3ML (100 UNITS/ML)

N21629 002 Dec 20, 2005 Mar CMFD

INSULIN RECOMBINANT HUMAN

POWDER; INHALATION

EXUBERA

PFIZER

1MG/INH

N21868 001 Jan 27, 2006 Jan NEWA

+

3MG/INH

N21868 002 Jan 27, 2006 Jan NEWA

ISONIAZID

INJECTABLE; INJECTION

ISONIAZID

AP	SANDOZ	100MG/ML	N40648 001	Jul 05, 2005	Jan	CAHN
----	--------	----------	------------	--------------	-----	------

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE MONONITRATE

>A>	AB	WEST WARD	30MG	N76813 002	Mar 30, 2006	Mar	NEWA
-----	----	-----------	------	------------	--------------	-----	------

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

AP	SANDOZ	15MG/ML	N76271 001	Oct 06, 2004	Jan	CAHN
----	--------	---------	------------	--------------	-----	------

AP		30MG/ML	N76271 002	Oct 06, 2004	Jan	CAHN
----	--	---------	------------	--------------	-----	------

LANSOPRAZOLE; NAPROXEN

CAPSULE, DELAYED REL PELLETS, TABLET; ORAL

PREVACID NAPRAPAC 250 (COPACKAGED)

	TAP PHARM	15MG, N/A; N/A, 250MG	N21507 002	Nov 14, 2003	Feb	CTNA
--	-----------	-----------------------	------------	--------------	-----	------

PREVACID NAPRAPAC 375 (COPACKAGED)

	TAP PHARM	15MG, N/A; N/A, 375MG	N21507 003	Nov 14, 2003	Feb	CTNA
--	-----------	-----------------------	------------	--------------	-----	------

PREVACID NAPRAPAC 500 (COPACKAGED)

+	TAP PHARM	15MG, N/A; N/A, 500MG	N21507 004	Nov 14, 2003	Feb	CTNA
---	-----------	-----------------------	------------	--------------	-----	------

LEVETIRACETAM

TABLET; ORAL

KEPPRA

>D>	+	UCB INC	750MG	N21035 003	Nov 30, 1999	Mar	CRLD
-----	---	---------	-------	------------	--------------	-----	------

>A>			750MG	N21035 003	Nov 30, 1999	Mar	CRLD
-----	--	--	-------	------------	--------------	-----	------

>A>	+		1GM	N21035 004	Jan 06, 2006	Mar	NEWA
-----	---	--	-----	------------	--------------	-----	------

LEVOBETAXOLOL HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

BETAXON

@	ALCON	EQ 0.5% BASE	N21114 001	Feb 23, 2000	Feb	CAHN
---	-------	--------------	------------	--------------	-----	------

LIDOCAINE HYDROCHLORIDE

JELLY; TOPICAL

ANESTACON

AT	+	POLYMEDICA	2%	N80429 001		Jan	CDFR
----	---	------------	----	------------	--	-----	------

LIDOCAINE; TETRACAINE

PATCH; TOPICAL

SYNERA

+	ENDO PHARMS	70MG; 70MG	N21623 001	Jun 23, 2005	Feb	CAHN
---	-------------	------------	------------	--------------	-----	------

LISINOPRIL

TABLET; ORAL

LISINOPRIL

AB	AUROBINDO	2.5MG	N77622 001	Feb 22, 2006	Feb	NEWA
----	-----------	-------	------------	--------------	-----	------

AB		5MG	N77622 002	Feb 22, 2006	Feb	NEWA
----	--	-----	------------	--------------	-----	------

AB		10MG	N77622 003	Feb 22, 2006	Feb	NEWA
----	--	------	------------	--------------	-----	------

AB		20MG	N77622 004	Feb 22, 2006	Feb	NEWA
----	--	------	------------	--------------	-----	------

TABLET; ORAL

LISINOPRIL

AB	AUROBINDO	30MG	N77622 005	Feb 22, 2006	Feb	NEWA
AB		40MG	N77622 006	Feb 22, 2006	Feb	NEWA

LORAZEPAM

TABLET; ORAL

LORAZEPAM

>A>	AB	MYLAN	0.5MG	N77657 001	Mar 16, 2006	Mar	NEWA
>A>	AB		1MG	N77657 002	Mar 16, 2006	Mar	NEWA
>A>	AB		2MG	N77657 003	Mar 16, 2006	Mar	NEWA

LOVASTATIN; NIACIN

TABLET, EXTENDED RELEASE; ORAL

ADVICOR

+	KOS LIFE	20MG;750MG	N21249 002	Dec 17, 2001	Feb	CMFD
---	----------	------------	------------	--------------	-----	------

LUBIPROSTONE

CAPSULE; ORAL

AMITIZA

+	SUCAMPO PHARMS	24UGM	N21908 001	Jan 31, 2006	Jan	NEWA
---	----------------	-------	------------	--------------	-----	------

>A> MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE

>A> TABLET, CHEWABLE; ORAL

>A> ZEGERID

>A>	SANTARUS	700MG;20MG;600MG	N21850 001	Mar 24, 2006	Mar	NEWA
>A>	+	700MG;40MG;600MG	N21850 002	Mar 24, 2006	Mar	NEWA

MEDROXYPROGESTERONE ACETATE

INJECTABLE; SUBCUTANEOUS

DEPO-SUBQ PROVERA 104

+	PHARMACIA AND UPJOHN	104MG/0.65ML	N21583 001	Dec 17, 2004	Jan	CAHN
---	----------------------	--------------	------------	--------------	-----	------

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGESTROL ACETATE

AB	APOTEX	40MG/ML	N77404 001	Feb 16, 2006	Jan	NEWA
----	--------	---------	------------	--------------	-----	------

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

	@	ROXANE	600MG	N84332 001		Jan	DISC
	@	SANDOZ	200MG	N14547 002		Jan	DISC
	@		400MG	N14547 001		Jan	DISC
	@		400MG	N80655 001		Jan	DISC
	@	SCHERER LABS	400MG	N83343 001		Jan	DISC
	@	TABLICAPS	400MG	N83494 001		Jan	DISC
AA	+	WATSON LABS	200MG	N83304 001		Jan	CRLD
	@		200MG	N85720 001		Jan	DISC
	+		400MG	N83308 001		Jan	CRLD
	@		400MG	N85721 001		Jan	DISC
		MILTOWN					
	@	MEDPOINTE PHARM HLC	200MG	N09698 004		Jan	DISC
	@		400MG	N09698 002		Jan	DISC

TABLET; ORAL

TRANMEP

@ SOLVAY

400MG

N16249 001

Jan DISC

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

GLUMETZA

BX DEPOMED INC 500MG

N21748 001 Jun 03, 2005 Jan CAHN

BX 1GM

N21748 002 Jun 03, 2005 Jan CAHN

METFORMIN HYDROCHLORIDE

AB SUN PHARM INDS (IN) 500MG

N77336 001 Feb 09, 2006 Jan NEWA

AB 750MG

N77336 002 Feb 09, 2006 Jan NEWA

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

METADATE CD

BX UCB INC 40MG

N21259 004 Feb 19, 2006 Feb NEWA

50MG

N21259 005 Feb 19, 2006 Feb NEWA

+

60MG

N21259 006 Feb 19, 2006 Feb NEWA

RITALIN LA

BX + NOVARTIS 40MG

N21284 003 Jun 05, 2002 Feb CTEC

MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE

OINTMENT; TOPICAL

VUSION

+ BARRIER 0.25%;81.35%;15%

N21026 001 Feb 16, 2006 Feb NEWA

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

>D> AP HOSPIRA EQ 5MG BASE/ML

N75293 002 Jun 20, 2000 Mar CRLD

>A> AP + EQ 5MG BASE/ML

N75293 002 Jun 20, 2000 Mar CRLD

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

MINOCIN

AB TRIAX PHARMS EQ 50MG BASE

N50649 001 May 31, 1990 Feb CAHN

@ EQ 75MG BASE

N50649 003 Feb 12, 2001 Feb CAHN

AB + EQ 100MG BASE

N50649 002 May 31, 1990 Feb CAHN

MIRTAZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL

MIRTAZAPINE

AB AUROBINDO PHARMA LTD 45MG

N77376 004 Feb 28, 2006 Feb NEWA

AB BARR 45MG

N76307 003 Feb 28, 2006 Feb NEWA

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE

>A> AP AM PHARM EQ 20MG BASE/10ML (2MG/ML)

N77496 001 Apr 11, 2006 Mar NEWA

>A> AP EQ 25MG BASE/12.5ML (2MG/ML)

N77496 002 Apr 11, 2006 Mar NEWA

>A> AP EQ 30MG BASE/15ML (2MG/ML)

N77496 003 Apr 11, 2006 Mar NEWA

>A> AP BEDFORD EQ 20MG BASE/10ML (2MG/ML)

N76611 001 Apr 11, 2006 Mar NEWA

>A> AP EQ 25MG BASE/12.5ML (2MG/ML)

N76611 002 Apr 11, 2006 Mar NEWA

>A> AP EQ 30MG BASE/15ML (2MG/ML)

N76611 003 Apr 11, 2006 Mar NEWA

INJECTABLE; INJECTION

>A> MITOXANTRONE

>A>	AP	MAYNE PHARMA USA	EQ 20MG BASE/10ML (2MG/ML)	N76871 001	Apr 11, 2006	Mar	NEWA
>A>	AP		EQ 25MG BASE/12.5ML (2MG/ML)	N76871 002	Apr 11, 2006	Mar	NEWA
>A>	AP		EQ 30MG BASE/15ML (2MG/ML)	N76871 003	Apr 11, 2006	Mar	NEWA
>A>	AP	SICOR PHARMS	EQ 20MG BASE/10ML (2MG/ML)	N77356 001	Apr 11, 2006	Mar	NEWA
>A>	AP		EQ 25MG BASE/12.5ML (2MG/ML)	N77356 002	Apr 11, 2006	Mar	NEWA
>A>	AP		EQ 30MG BASE/15ML (2MG/ML)	N77356 003	Apr 11, 2006	Mar	NEWA

NOVANTRONE

>D>	+	SERONO INC	EQ 20MG BASE/10 MG (2MG/ML)	N19297 001	Dec 23, 1987	Mar	CFTG
>A>	AP	+	EQ 20MG BASE/10ML(2MG/ML)	N19297 001	Dec 23, 1987	Mar	CFTG
>D>	+		EQ 25MG BASE/12.5ML (2MG/ML)	N19297 002	Dec 23, 1987	Mar	CFTG
>A>	AP	+	EQ 25MG BASE/12.5ML (2MG/ML)	N19297 002	Dec 23, 1987	Mar	CFTG
>D>	+		EQ 30MG BASE/15ML (2MG/ML)	N19297 003	Dec 23, 1987	Mar	CFTG
>A>	AP	+	EQ 30MG BASE/15ML (2MG/ML)	N19297 003	Dec 23, 1987	Mar	CFTG

MOMETASONE FUROATELOTION; TOPICALMOMETASONE FUROATE

>D>	AB	AGIS INDS	0.1%	N77180 001	Apr 06, 2005	Mar	CAHN
>A>	AB	PERRIGO	0.1%	N77180 001	Apr 06, 2005	Mar	CAHN
	AB	TARO	0.1%	N76788 001	Mar 15, 2006	Feb	NEWA

MORPHINE SULFATEINJECTABLE; INJECTIONMORPHINE SULFATE

>A>		HOSPIRA	5MG/ML	N19916 002	Mar 30, 2006	Mar	NEWA
-----	--	---------	--------	------------	--------------	-----	------

NEOMYCIN SULFATE; POLYMYXIN B SULFATESOLUTION; IRRIGATIONNEOSPORIN AND POLYMYXIN B SULFATE

AT		X GEN PHARMS	EQ 40MG BASE/ML;200,000 UNITS/ML	N65106 001	Jan 31, 2006	Jan	NEWA
AT			EQ 800MG BASE/20ML;4,000,000 UNITS/20ML (EQ 40MG BASE/ML;200,000 UNITS/ML)	N65108 001	Jan 31, 2006	Jan	NEWA

NEOSPORIN G.U. IRRIGANT

AT	+	MONARCH PHARMS	EQ 40MG BASE/ML;200,000 UNITS/ML	N60707 001		Jan	CTEC
AT	+		EQ 800MG BASE/20ML;4,000,000 UNITS/20ML (EQ 40MG BASE/ML;200,000 UNITS/ML)	N60707 002		Jan	NEWA

NICARDIPINE HYDROCHLORIDEINJECTABLE; INJECTIONCARDENE

	+	PDL BIOPHARMA INC	2.5MG/ML	N19734 001	Jan 30, 1992	Jan	CAHN
--	---	-------------------	----------	------------	--------------	-----	------

NIFEDIPINETABLET, EXTENDED RELEASE; ORALAFEDITAB CR

AB1		WATSON LABS	30MG	N75128 001	Mar 10, 2000	Jan	CAHN
AB1			60MG	N75659 001	Oct 26, 2001	Jan	CAHN

OCTREOTIDE ACETATEINJECTABLE; INJECTIONOCTREOTIDE ACETATE

AP		AM PHARM	EQ 0.2MG BASE/ML	N77450 001	Feb 10, 2006	Jan	NEWA
AP			EQ 1MG BASE/ML	N77450 002	Feb 10, 2006	Jan	NEWA

INJECTABLE; INJECTIONOCTREOTIDE ACETATE (PRESERVATIVE FREE)

AP	AM PHARM	EQ 0.05MG BASE/ML	N77457 001	Feb 10, 2006	Jan	NEWA
AP		EQ 0.1MG BASE/ML	N77457 002	Feb 10, 2006	Jan	NEWA
AP		EQ 0.5MG BASE/ML	N77457 003	Feb 10, 2006	Jan	NEWA

OFLOXACINTABLET; ORALOFLOXACIN

AB	DR REDDYS LABS LTD	200MG	N77098 001	Feb 10, 2006	Jan	NEWA
AB		300MG	N77098 002	Feb 10, 2006	Jan	NEWA
AB		400MG	N77098 003	Feb 10, 2006	Jan	NEWA

OMEPRAZOLE; SODIUM BICARBONATECAPSULE; ORALZEGERIDSANTARUS

		20MG;1.1GM	N21849 001	Feb 27, 2006	Feb	NEWA
--	--	------------	------------	--------------	-----	------

+		40MG;1.1GM	N21849 002	Feb 27, 2006	Feb	NEWA
---	--	------------	------------	--------------	-----	------

FOR SUSPENSION; ORALZEGERIDSANTARUS

		20MG/PACKET;1.68GM/PACKET	N21636 001	Jun 15, 2004	Feb	CAIN
--	--	---------------------------	------------	--------------	-----	------

+		40MG/PACKET;1.68GM/PACKET	N21706 001	Dec 21, 2004	Feb	CAIN
---	--	---------------------------	------------	--------------	-----	------

PENICILLIN V POTASSIUMFOR SOLUTION; ORALPENICILLIN V POTASSIUM

AA	AM ANTIBIOTICS	EQ 125MG BASE/5ML	N61529 001		Jan	CAHN
AA		EQ 250MG BASE/5ML	N61529 002		Jan	CAHN

TABLET; ORALPENICILLIN V POTASSIUM@ AM ANTIBIOTICS@

		EQ 250MG BASE	N61528 001		Jan	CAHN
		EQ 500MG BASE	N61528 002		Jan	CAHN

PERGOLIDE MESYLATETABLET; ORALPERMAX

AB	VALEANT	EQ 0.05MG BASE	N19385 001	Dec 30, 1988	Jan	CRLD
AB	+	EQ 0.25MG BASE	N19385 002	Dec 30, 1988	Jan	CRLD

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDESYRUP; ORALPROMETH VC PLAIN

+	ALPHARMA US PHARMS	5MG/5ML;6.25MG/5ML	N88761 001	Nov 08, 1984	Jan	CTEC
---	--------------------	--------------------	------------	--------------	-----	------

PROMETHAZINE VC PLAIN@ MORTON GROVE

		5MG/5ML;6.25MG/5ML	N88897 001	Jan 04, 1985	Jan	DISC
--	--	--------------------	------------	--------------	-----	------

PHYTONADIONEINJECTABLE; INJECTIONAQUAMEPHYTON@ MERCK@

		1MG/0.5ML	N12223 002		Feb	DISC
		10MG/ML	N12223 001		Feb	DISC

VITAMIN K1

BP	+	HOSPIRA	1MG/0.5ML	N87954 001	Jul 25, 1983	Feb	CRLD
	+		10MG/ML	N87955 001	Jul 25, 1983	Feb	CRLD

PILOCARPINE HYDROCHLORIDE

TABLET; ORAL

PILOCARPINE HYDROCHLORIDE

>A>	AB	IMPAX LABS	5MG	N77248 001	Mar 31, 2006	Mar	NEWA
>A>	AB		7.5MG	N77248 002	Mar 31, 2006	Mar	NEWA
SALAGEN							
>D>	+	MGI PHARMA INC	7.5MG	N20237 002	Apr 18, 2003	Mar	CFTG
>A>	AB	+	7.5MG	N20237 002	Apr 18, 2003	Mar	CFTG

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL

KLOR-CON

AB	UPSHER SMITH	8MEQ	N19123 001	Apr 17, 1986	Jan	CRLD	
POTASSIUM CHLORIDE							
AB	+	COPLEY PHARM	8MEQ	N70618 001	Sep 09, 1987	Jan	CRLD

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

PRAZOSIN HYDROCHLORIDE

@ CLONMEL HLTHCARE

EQ 1MG BASE

N72705 001 May 16, 1989 Jan DISC

@

EQ 5MG BASE

N72707 001 May 16, 1989 Jan DISC

PREDNISOLONE ACETATE

>D>	INJECTABLE; INJECTION						
>D>	PREDNISOLONE ACETATE						
>D>	+	STERIS	25MG/ML	N83398 001		Mar	DISC
>A>	@		25MG/ML	N83398 001		Mar	DISC
>D>	+		50MG/ML	N83764 001		Mar	DISC
>A>	@		50MG/ML	N83764 001		Mar	DISC

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY; RECTAL

PHENERGAN

>D>	PHENERGAN						
>D>	AB	WYETH PHARMS INC	12.5MG	N10926 002		Mar	DISC
>A>	@		12.5MG	N10926 002		Mar	DISC
>D>	AB	+	25MG	N10926 001		Mar	DISC
>A>	@		25MG	N10926 001		Mar	DISC

PROMETHAZINE HYDROCHLORIDE

>D>	AB	G AND W LABS	25MG	N40428 001	Feb 05, 2002	Mar	CRLD
>A>	AB	+	25MG	N40428 001	Feb 05, 2002	Mar	CRLD
PROMETHEGAN							
	+	G AND W LABS	50MG	N87165 001	Aug 14, 1987	Jan	CRLD

PROPOFOL

INJECTABLE; INJECTION

PROPOFOL

>A>	AB	HOSPIRA	10MG/ML	N77908 001	Mar 17, 2006	Mar	NEWA
-----	----	---------	---------	------------	--------------	-----	------

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

PROPOXYPHENE HYDROCHLORIDE

>D>	AA	IVAX PHARMS	65MG	N80269 001		Mar	CAHN
>A>	AA	PAR PHARM	65MG	N80269 001		Mar	CAHN

PROPRANOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

PROPRANOLOL HYDROCHLORIDE

AP	SANDOZ	1MG/ML	N76400 001	Feb 26, 2003	Jan	CAHN
----	--------	--------	------------	--------------	-----	------

PYRIDOSTIGMINE BROMIDE

INJECTABLE; INJECTION

REGONOL

AP	SANDOZ	5MG/ML	N17398 001		Jan	CAHN
----	--------	--------	------------	--	-----	------

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

AB	TORPHARM	EQ 5MG BASE	N76240 001	Jan 26, 2006	Jan	NEWA
AB		EQ 10MG BASE	N76240 002	Jan 26, 2006	Jan	NEWA
AB		EQ 20MG BASE	N76240 003	Jan 26, 2006	Jan	NEWA
AB		EQ 40MG BASE	N76240 004	Jan 26, 2006	Jan	NEWA

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL

QUINIDINE GLUCONATE

BX	+	MUTUAL PHARM	324MG	N89338 001	Feb 11, 1987	Jan	CTEC
BX		WATSON LABS	324MG	N87810 001	Sep 29, 1982	Jan	CMFD

QUINIDINE SULFATE

TABLET; ORAL

QUINIDINE SULFATE

	@	CLONMEL HLTHCARE	200MG	N87011 001		Jan	DISC
	@	LANNETT	200MG	N83743 001		Jan	DISC
	@	MUTUAL PHARM	100MG	N81029 001	Apr 14, 1989	Jan	DISC
	@	PHARM FORM	200MG	N83808 001		Jan	DISC
	@	SANDOZ	200MG	N84631 001		Jan	DISC
	@		200MG	N84914 001		Jan	DISC
AB			200MG	N88072 002		Jan	NEWA
	@		300MG	N89839 001	Sep 29, 1988	Jan	DISC
	@	WATSON LABS	200MG	N83288 001		Jan	DISC
	@		200MG	N85140 002		Jan	DISC

RANITIDINE

INJECTABLE; INJECTION

RANITIDINE

AP	BEDFORD	EQ 25MG BASE/ML	N77458 001	Feb 16, 2006	Feb	NEWA
----	---------	-----------------	------------	--------------	-----	------

RANOLAZINE

TABLET, EXTENDED RELEASE; ORAL

RANEXA

+	CV THERAP	500MG	N21526 002	Jan 27, 2006	Jan	NEWA
---	-----------	-------	------------	--------------	-----	------

RISPERIDONE

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERDAL

>D>	@	JANSSEN PHARMA	3MG	N21444 004	Dec 23, 2004	Mar	CMFD
>A>			3MG	N21444 004	Dec 23, 2004	Mar	CMFD
>D>	@		4MG	N21444 005	Dec 23, 2004	Mar	CMFD

	TABLET, ORALLY DISINTEGRATING; ORAL								
	RISPERDAL								
>A>	JANSSEN PHARMA	4MG		N21444	005	Dec 23, 2004	Mar	CMFD	
>A>	<u>SELEGILINE</u>								
>A>	FILM, EXTENDED RELEASE; TRANSDERMAL								
>A>	EMSAM								
>A>	SOMERSET	6MG/24HR		N21336	001	Feb 27, 2006	Mar	CAIN	
>A>		9MG/24HR		N21336	002	Feb 27, 2006	Mar	CAIN	
>A>	+	12MG/24HR		N21336	003	Feb 27, 2006	Mar	CAIN	
>D>	<u>SELEGILINE HYDROCHLORIDE</u>								
>D>	FILM, EXTENDED RELEASE; TRANSDERMAL								
>D>	EMSAM								
>D>	SOMERSET	6MG/24HR		N21336	001	Feb 27, 2006	Mar	CAIN	
		6MG/24HR		N21336	001	Feb 27, 2006	Feb	NEWA	
>D>		9MG/24HR		N21336	002	Feb 27, 2006	Mar	CAIN	
		9MG/24HR		N21336	002	Feb 27, 2006	Feb	NEWA	
>D>	+	12MG/24HR		N21336	003	Feb 27, 2006	Mar	CAIN	
	+	12MG/24HR		N21336	003	Feb 27, 2006	Feb	NEWA	
	<u>SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE</u>								
	TABLET; ORAL								
>A>	OSMOPREP								
>A>	+	SALIX PHARMS	0.398GM;1.102GM	N21892	001	Mar 16, 2006	Mar	NEWA	
	<u>SPIRONOLACTONE</u>								
	TABLET; ORAL								
	SPIRONOLACTONE								
AB	PUREPAC PHARM	25MG		N40353	003	Mar 15, 2006	Feb	NEWA	
	<u>SUCCINYLCHOLINE CHLORIDE</u>								
	INJECTABLE; INJECTION								
	ANECTINE								
AP	+	SANDOZ	20MG/ML	N08453	002		Jan	CAHN	
	@		50MG/ML	N08453	003		Jan	CAHN	
	@		500MG/VIAL	N08453	001		Jan	CAHN	
	@		1GM/VIAL	N08453	004		Jan	CAHN	
	<u>SUMATRIPTAN SUCCINATE</u>								
	INJECTABLE; SUBCUTANEOUS								
	IMITREX								
+	GLAXOSMITHKLINE	EQ 6MG BASE/0.5ML (12MG/ML)		N20080	001	Dec 28, 1992	Feb	CDFR	
	IMITREX STATDOSE								
+	GLAXOSMITHKLINE	EQ 4MG BASE/0.5ML (8MG/ML)		N20080	002	Feb 01, 2006	Feb	NEWA	
+		EQ 6MG BASE/0.5ML (12MG/ML)		N20080	003	Dec 23, 1996	Feb	NEWA	
	<u>SUNITINIB MALATE</u>								
	CAPSULE; ORAL								
	SUTENT								
	PFIZER	12.5MG		N21938	001	Jan 26, 2006	Jan	NEWA	
		25MG		N21938	002	Jan 26, 2006	Jan	NEWA	
+		50MG		N21938	003	Jan 26, 2006	Jan	NEWA	

TERCONAZOLE

SUPPOSITORY; VAGINAL

TERAZOL 3

>D>	+	ORTHO MCNEIL PHARM	80MG	N19641 001	May 24, 1988	Mar	CFTG
>A>	AB	+	80MG	N19641 001	May 24, 1988	Mar	CFTG
>A>		TERCONAZOLE					
>A>	AB	PERRIGO NEW YORK	80MG	N77149 001	Mar 17, 2006	Mar	NEWA

TESTOSTERONE

GEL; TRANSDERMAL

ANDROGEL

AB	+	UNIMED PHARMS	1%	N21015 001	Feb 28, 2000	Jan	CTEC
		TESTOSTERONE					
AB		WATSON LABS	1%	N76737 001	Jan 27, 2006	Jan	NEWA

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

DELATESTRYL

		@ INDEVUS PHARMS	200MG/ML	N09165 001		Jan	CAHN
AO	+		200MG/ML	N09165 003		Jan	CAHN

THALLOUS CHLORIDE, TL-201

INJECTABLE; INJECTION

THALLOUS CHLORIDE TL 201

AP		TRACE RADIOCHEMICALS	1mCi/ML	N75569 001	Nov 21, 2001	Feb	CAHN
----	--	----------------------	---------	------------	--------------	-----	------

TINIDAZOLE

TABLET; ORAL

TINDAMAX

		MISSION PHARMA	250MG	N21618 001	May 17, 2004	Jan	CAHN
	+		500MG	N21618 002	May 17, 2004	Jan	CAHN

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

@ IVAX PHARMS

50MG

N75963 001	Jul 03, 2002	Jan	DISC
------------	--------------	-----	------

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION

ARISTOCORT

@ SANDOZ

25MG/ML

N11685 003		Jan	CAHN
------------	--	-----	------

@

40MG/ML

N12802 001		Jan	CAHN
------------	--	-----	------

TRIAMCINOLONE HEXACETONIDE

INJECTABLE; INJECTION

ARISTOSPAN

+	SANDOZ	5MG/ML	N16466 001		Jan	CAHN
+		20MG/ML	N16466 002		Jan	CAHN

TRIPLENNAMINE HYDROCHLORIDE

TABLET; ORAL

PBZ

@ NOVARTIS

50MG

N05914 002		Jan	DISC
------------	--	-----	------

>D> TROLEANDOMYCIN

>D> CAPSULE; ORAL

>D> TAO

>D> + PFIZER EQ 250MG BASE N50336 002 Mar DISC

>A> @ EQ 250MG BASE N50336 002 Mar DISC

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS; OPHTHALMIC

RESCULA

+ R TECH UENO LTD 0.15% N21214 001 Aug 03, 2000 Feb CAHN

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

AP + BEDFORD 20MG/VIAL N75549 002 Jun 13, 2000 Jan CRLD

ZIDOVUDINE

CAPSULE; ORAL

RETROVIR

>D> + GLAXOSMITHKLINE 100MG N19655 001 Mar 19, 1987 Mar CFTG

>A> AB + 100MG N19655 001 Mar 19, 1987 Mar CFTG

>A> ZIDOVUDINE

>A> AB AUROBINDO PHARMA LTD 100MG N78128 001 Mar 27, 2006 Mar NEWA

ZIPRASIDONE HYDROCHLORIDE

>A> SUSPENSION; ORAL

>A> GEODON

>A> + PFIZER INC EQ 10MG BASE/ML N21483 001 Mar 29, 2006 Mar NEWA

ZONISAMIDE

CAPSULE; ORAL

ZONISAMIDE

AB GLENMARK PHARMS 25MG N77651 001 Jan 30, 2006 Jan NEWA

AB 50MG N77651 002 Jan 30, 2006 Jan NEWA

AB 100MG N77651 003 Jan 30, 2006 Jan NEWA

>A> AB SUN PHARM INDS (IN) 25MG N77634 001 Mar 17, 2006 Mar NEWA

>A> AB 50MG N77634 002 Mar 17, 2006 Mar NEWA

>A> AB 100MG N77634 003 Mar 17, 2006 Mar NEWA

OTC DRUG PRODUCT LIST - 26TH EDITION

OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2006

2-1

CROMOLYN SODIUM

SPRAY, METERED; NASAL

CROMOLYN SODIUM

ALPHARMA US PHARMS	5.2MG/SPRAY	N74800	001	Jul 26, 2001	Jan	CPOT
+ BAUSCH AND LOMB	5.2MG/SPRAY	N75702	001	Jul 03, 2001	Jan	CRLD
NASALCROM						
@ PHARMACIA UPJOHN	5.2MG/SPRAY	N20463	001	Jan 03, 1997	Jan	DISC

KETOPROFEN

TABLET; ORAL

ACTRON

@ BAYER	12.5MG	N20499	001	Oct 06, 1995	Feb	DISC
---------	--------	--------	-----	--------------	-----	------

ORUDIS KT

@ WYETH CONS	12.5MG	N20429	001	Oct 06, 1995	Feb	DISC
--------------	--------	--------	-----	--------------	-----	------

LOPERAMIDE HYDROCHLORIDE

>D> SOLUTION; ORAL

>D> IMODIUM A-D

+ MCNEIL	1MG/7.5ML	N19487	002	Jul 08, 2004	Mar	CDFR
----------	-----------	--------	-----	--------------	-----	------

>A> SUSPENSION; ORAL

>A> IMODIUM A-D

+ MCNEIL	1MG/7.5ML	N19487	002	Jul 08, 2004	Mar	CDFR
----------	-----------	--------	-----	--------------	-----	------

LORATADINE

TABLET; ORAL

LORATADINE

APOTEX	10MG	N76471	001	Feb 14, 2006	Jan	NEWA
--------	------	--------	-----	--------------	-----	------

MINOXIDIL

AEROSOL, FOAM; TOPICAL

MEN'S ROGAINE

+ PHARMACIA AND UPJOHN	5%	N21812	001	Jan 20, 2006	Jan	NEWA
------------------------	----	--------	-----	--------------	-----	------

NAPROXEN SODIUM

CAPSULE; ORAL

NAPROXEN SODIUM

+ BANNER PHARMACAPS	EQ 200MG BASE	N21920	001	Feb 17, 2006	Feb	NEWA
---------------------	---------------	--------	-----	--------------	-----	------

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICORETTE

>A> GLAXOSMITHKLINE	EQ 2MG BASE	N18612	004	Sep 25, 2000	Mar	CRLD
---------------------	-------------	--------	-----	--------------	-----	------

>A>	EQ 2MG BASE	N18612	003	Dec 23, 1998	Mar	CRLD
-----	-------------	--------	-----	--------------	-----	------

>A>	EQ 4MG BASE	N20066	004	Sep 25, 2000	Mar	CRLD
-----	-------------	--------	-----	--------------	-----	------

>A>	EQ 4MG BASE	N20066	003	Dec 23, 1998	Mar	CRLD
-----	-------------	--------	-----	--------------	-----	------

NICORETTE (MINT)

>D> + GLAXOSMITHKLINE	EQ 2MG BASE	N18612	003	Dec 23, 1998	Mar	CRLD
-----------------------	-------------	--------	-----	--------------	-----	------

>D> +	EQ 4MG BASE	N20066	003	Dec 23, 1998	Mar	CRLD
-------	-------------	--------	-----	--------------	-----	------

NICORETTE (ORANGE)

>D> + GLAXOSMITHKLINE	EQ 2MG BASE	N18612	004	Sep 25, 2000	Mar	CRLD
-----------------------	-------------	--------	-----	--------------	-----	------

>D> +	EQ 4MG BASE	N20066	004	Sep 25, 2000	Mar	CRLD
-------	-------------	--------	-----	--------------	-----	------

TROCHE/LOZENGE; ORAL
NICOTINE POLACRILEX
PERRIGO R AND D

EQ 2MG BASE
EQ 4MG BASE

N77007 001 Jan 31, 2006 Jan NEWA
N77007 002 Jan 31, 2006 Jan NEWA

RANITIDINE HYDROCHLORIDE

TABLET; ORAL
RANITIDINE
WOCKHARDT

EQ 75MG BASE

N76760 001 Feb 24, 2006 Feb NEWA

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 03 MARCH 2006

NO MARCH 2006 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO MARCH 2006 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE; LAMIVUDINE - EPZICOM</u>					
021652 001	5034394	Dec 18, 2011	DS DP	D-40	Aug 02, 2007
	5034394*PED	Jun 18, 2012			
	5047407	Nov 17, 2009	DS DP	U-257	
	5047407*PED	May 17, 2010			
	5089500	Jun 26, 2009		U-257	
	5089500*PED	Dec 26, 2009			
	5905082	May 18, 2016	DS DP		
	5905082*PED	Nov 18, 2016			
	6294540	May 14, 2018	DS DP	U-257	
	6294540*PED	Nov 14, 2018			
<u>ALBUTEROL SULFATE - PROAIR HFA</u>					
021457 001				I-235	Feb 03, 2009
<u>ALENDRONATE SODIUM; CHOLECALCIFEROL - FOSAMAX PLUS D</u>					
021762 001				NC	Apr 07, 2008
<u>ALFUZOSIN HYDROCHLORIDE - UROXATRAL</u>					
021287 001	4661491	May 27, 2007		U-706	
<u>ANIDULAFUNGIN - ERAXIS</u>					
021632 001	>A> 5965525	Oct 12, 2016	DS DP	U-540	NCE Feb 17, 2011
	>A> 6384013	Mar 19, 2012	DS		
	>A> 6743777	Mar 19, 2012		DP U-540	
	>A> 6960564	Apr 12, 2021		DP U-540	
<u>APREPITANT - EMEND</u>					
021549 001	5145684	Jan 25, 2011		DP	
<u>APREPITANT - EMEND</u>					
021549 002	5145684	Jan 25, 2011		DP	
<u>ARIPIRAZOLE - ABILIFY</u>					
021436 001				I-488	Mar 01, 2008
<u>ARIPIRAZOLE - ABILIFY</u>					
021436 002				I-488	Mar 01, 2008
<u>ARIPIRAZOLE - ABILIFY</u>					
021436 003				I-488	Mar 01, 2008
<u>ARIPIRAZOLE - ABILIFY</u>					
021436 004				I-488	Mar 01, 2008
<u>ARIPIRAZOLE - ABILIFY</u>					
021436 005				I-488	Mar 01, 2008
<u>ARIPIRAZOLE - ABILIFY</u>					
021436 006				I-488	Mar 01, 2008
<u>ARIPIRAZOLE - ABILIFY</u>					
021713 001	6977257	Apr 24, 2022	DS DP	I-488	Mar 01, 2008
<u>AZELASTINE HYDROCHLORIDE - ASTELIN</u>					
020114 001				D-102	Feb 17, 2009
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX</u>					
021852 001	4866048	Dec 29, 2007	DS DP	U-88	NC Jan 09, 2009
	4866048	Dec 29, 2007	DS DP	U-193	
	5763426	Jun 09, 2015	DS DP		
	6753013	Jan 27, 2020		DP U-193	
	6753013	Jan 27, 2020		DP U-88	
<u>BIVALIRUDIN - ANGIOMAX</u>					
020873 001				I-486	Nov 30, 2008
<u>BORTEZOMIB - VELCADE</u>					
021602 001				ODE	Mar 25, 2012

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>					
021770 001	5424078	Jun 13, 2012	DP		
	5424078*PED	Dec 13, 2012			
	6562873	Jul 10, 2021	DP		
	6562873*PED	Jan 10, 2022			
	6627210	Jul 18, 2021	DP		
	6627210*PED	Jan 18, 2022			
	6641834	Jul 28, 2021	DP		
	6641834*PED	Jan 28, 2022			
	6673337	Jul 26, 2021	DP		
	6673337*PED	Jan 26, 2022			
<u>BROMFENAC SODIUM - XIBROM</u>					
021664 001				I-485	Jan 27, 2009
<u>BUDESONIDE - PULMICORT RESPULES</u>					
020929 001	6899099	Dec 23, 2018	U-645		
	6899099*PED	Jun 23, 2019			
<u>BUDESONIDE - PULMICORT RESPULES</u>					
020929 002	6899099	Dec 23, 2018	U-645		
	6899099*PED	Jun 23, 2019			
<u>BUDESONIDE - RHINOCORT</u>					
020746 001	6986904	Apr 29, 2017	DP U-699		
<u>BUDESONIDE - RHINOCORT</u>					
020746 002	6986904	Apr 29, 2017	DP U-699		
<u>CALCIUM CARBONATE; RISEDRONATE SODIUM - ACTONEL WITH CALCIUM (COPACKAGED)</u>					
021823 001				M-52	Jan 24, 2009
<u>CEFDITOREN PIVOXIL - SPECTRACEF</u>					
021222 001	4839350	Jan 14, 2009	DS DP		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP SINGLE SWABSTICK</u>					
021555 002	>A> 5690958	Sep 30, 2016	DP		
<u>CICLOPIROX - LOPROX</u>					
020519 001	>A> 7018656	Sep 05, 2018	DP		
	>A> 7026337	Apr 02, 2018		U-714	
<u>CONIVAPTAN HYDROCHLORIDE - VAPRISOL</u>					
021697 001	5723606	Mar 03, 2015	DS DP	U-698	
<u>DESFLURANE - SUPRANE</u>					
020118 001	5617906	Apr 08, 2014	DP		
<u>DESLOMATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX D 24 HOUR</u>					
021605 001	6979463	Mar 28, 2022	DP		
<u>DESLOMATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX-D 12 HOUR</u>					
021313 001	>A> 4659716	Apr 21, 2006	DP	U-707	
	>A> 4659716*PED	Oct 21, 2006			
	>A> 6100274	Jul 07, 2019	DP		
	>A> 6100274*PED	Jan 07, 2010			
	>A> 6709676	Feb 18, 2021	DP	U-707	
<u>DOCETAXEL - TAXOTERE</u>					
020449 001	5750561	Jul 03, 2012	DP	>A> I-490	Mar 22, 2009
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT ODT</u>					
021720 001	>A> 4895841	Nov 25, 2010	DS DP	U-713	
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT ODT</u>					
021720 002	>A> 4895841	Nov 25, 2010	DS DP	U-713	
<u>DROSPIRENONE; ETHINYL ESTRADIOL - YAZ</u>					
021676 001				>A> NP	Mar 16, 2009
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>					
021153 001				I-484	Nov 24, 2007
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>					
021153 002				I-484	Nov 24, 2007
<u>ETHINYL ESTRADIOL; NORELGESTROMIN - ORTHO EVRA</u>					
021180 001	5876746	Nov 20, 2015	DP	U-514	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LOESTRIN 24 FE</u>					
021871 001	>A> 5552394	Jul 22, 2014	U-1	NP	Feb 17, 2009
<u>FENOFIBRATE - FENOFIBRATE</u>					
076433 001				PC	May 22, 2006
<u>FENOFIBRATE - FENOFIBRATE</u>					
076433 002				PC	May 22, 2006
<u>FENOFIBRATE - LIPOFEN</u>					
021612 001	5545628	Jan 10, 2015	U-701		
<u>FENOFIBRATE - LIPOFEN</u>					
021612 002	5545628	Jan 10, 2015	U-701		
<u>FENOFIBRATE - LIPOFEN</u>					
021612 003	5545628	Jan 10, 2015	U-701		
<u>FLUNISOLIDE - AEROSPAN HFA</u>					
021247 001				NP	Jan 27, 2009
<u>FLUOCINOLONE ACETONIDE - RETISERT</u>					
021737 001	6217895	Mar 22, 2019	DP U-708		
	>A> 6548078	Mar 22, 2019	DP U-708		
<u>FLUOCINONIDE - VANOS</u>					
021758 001				I-487	Mar 02, 2009
<u>FLUOXETINE HYDROCHLORIDE - PROZAC WEEKLY</u>					
021235 001	>A> RE39030	May 29, 2017	DP U-397		
	>A> RE39030	May 29, 2017	DP U-396		
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>					
021433 001	>A> 5658549	Sep 19, 2014	DP U-710	NPP	Feb 28, 2009
	>A> 5674472	Oct 07, 2014	DP		
	>A> 6251368	Dec 04, 2012	DP		
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>					
021433 002	>A> 5658549	Sep 19, 2014	DP U-710	NPP	Feb 28, 2009
	>A> 5674472	Oct 07, 2014	DP		
	>A> 6251368	Dec 04, 2012	DP		
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>					
021433 003	>A> 5658549	Sep 19, 2014	DP U-710	NPP	Feb 28, 2009
	>A> 5674472	Oct 07, 2014	DP		
	>A> 6251368	Dec 04, 2012	DP		
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 100/50</u>					
021077 001	4992474	Feb 12, 2008	U-211		
	4992474*PED	Aug 12, 2008	U-211		
	5126375	Feb 12, 2008			
	5126375*PED	Aug 12, 2008			
	5225445	Feb 12, 2008	U-211		
	5225445*PED	Aug 12, 2008	U-211		
	6536427	Mar 01, 2011	DP		
	6536427*PED	Sep 01, 2011			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 250/50</u>					
021077 002	4992474	Feb 12, 2008	U-211		
	4992474*PED	Aug 12, 2008	U-211		
	5126375	Feb 12, 2008			
	5126375*PED	Aug 12, 2008			
	5225445	Feb 12, 2008	U-211		
	5225445*PED	Aug 12, 2008	U-211		
	6536427	Mar 01, 2011	DP		
	6536427*PED	Sep 01, 2011			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 500/50</u>					
021077 003	4992474	Feb 12, 2008	U-211		
	4992474*PED	Aug 12, 2008	U-211		
	5126375	Feb 12, 2008			
	5126375*PED	Aug 12, 2008			
	5225445	Feb 12, 2008	U-211		
	5225445*PED	Aug 12, 2008	U-211		
	6536427	Mar 01, 2011	DP		
	6536427*PED	Sep 01, 2011			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FROVATRIPTAN SUCCINATE - FROVA</u>					
021006 001	>A> 5464864	Nov 07, 2015	U-436		
<u>FULVESTRANT - FASLODEX</u>					
021344 001	4659516	Oct 01, 2006			
<u>GLIMEPIRIDE - AMARYL</u>					
020496 001				M-54 PED	Nov 28, 2008 May 28, 2009
<u>GLIMEPIRIDE - AMARYL</u>					
020496 002				M-54 PED	Nov 28, 2008 May 28, 2009
<u>GLIMEPIRIDE - AMARYL</u>					
020496 003				M-54 PED	Nov 28, 2008 May 28, 2009
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>					
021700 001	5002953	Sep 17, 2011	DS DP	U-690	
	5002953*PED	Mar 17, 2012			
	5741803	Apr 21, 2015	DS DP	U-690	
	5741803*PED	Oct 21, 2015			
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>					
021700 002	5002953	Sep 17, 2011	DS DP	U-690	
	5002953*PED	Mar 17, 2012			
	5741803	Apr 21, 2015	DS DP	U-690	
	5741803*PED	Oct 21, 2015			
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>					
021700 003	5002953	Sep 17, 2011	DS DP	U-690	
	5002953*PED	Mar 17, 2012			
	5741803	Apr 21, 2015	DS DP	U-690	
	5741803*PED	Oct 21, 2015			
<u>HYALURONIDASE RECOMBINANT HUMAN - HYLENEX RECOMBINANT</u>					
021859 001				NCE	Dec 02, 2010
<u>IBANDRONATE SODIUM - BONIVA</u>					
021455 001	4927814	Jul 09, 2007	DS DP	U-642	
	6143326	Apr 21, 2017		U-642	
<u>IBANDRONATE SODIUM - BONIVA</u>					
021858 001	4927814	Jul 09, 2007	DS DP	U-700	NDF NCE
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR</u>					
021536 001				I-489	Oct 19, 2008
<u>INSULIN RECOMBINANT HUMAN - EXUBERA</u>					
021868 001	5740794	Apr 21, 2015	DP	>A> NP	Jan 27, 2009
	5997848	Mar 07, 2014		U-704	
	6051256	Mar 07, 2014	DP		
	6257233	May 14, 2019		U-704	
	6423344	Mar 07, 2014	DP		
	6543448	Sep 21, 2014	DP		
	6546929	May 14, 2019		U-704	
	6582728	Jun 24, 2020	DP		
	6592904	Mar 07, 2014	DP		
	6685967	Sep 11, 2018	DP		
	6737045	Mar 07, 2014		U-704	
	RE37872	Feb 12, 2010	DP		
	RE38385	Feb 12, 2010	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
INSULIN RECOMBINANT HUMAN - EXUBERA					
021868 002	5740794	Apr 21, 2015	DP	>A> NP	Jan 27, 2009
	5997848	Mar 07, 2014	U-704		
	6051256	Mar 07, 2014	DP		
	6257233	May 14, 2019	U-704		
	6423344	Mar 07, 2014	DP		
	6543448	Sep 21, 2014	DP		
	6546929	May 14, 2019	U-704		
	6582728	Jun 24, 2020	DP		
	6592904	Mar 07, 2014	DP		
	6685967	Sep 11, 2018	DP		
	6737045	Mar 07, 2014	U-704		
	RE37872	Feb 12, 2010	DP		
	RE38385	Feb 12, 2010	DP		
IPRATROPIUM BROMIDE - ATROVENT HFA					
021527 001	6983743	May 26, 2020	DP		
LANSOPRAZOLE - PREVACID					
020406 001	6749864	Feb 13, 2007	DP		
LANSOPRAZOLE - PREVACID					
020406 002	6749864	Feb 13, 2007	DP		
LANSOPRAZOLE - PREVACID					
021281 001	6749864	Feb 13, 2007	DP		
LANSOPRAZOLE - PREVACID					
021281 002	6749864	Feb 13, 2007	DP		
LANSOPRAZOLE - PREVACID					
021428 001	6749864	Feb 13, 2007	DP		
LANSOPRAZOLE - PREVACID					
021428 002	6749864	Feb 13, 2007	DP		
LANTHANUM CARBONATE - FOSRENOL					
021468 003	5968976	Mar 19, 2016	DP	U-613	
LANTHANUM CARBONATE - FOSRENOL					
021468 004	5968976	Mar 19, 2016	DP	U-613	
LENALIDOMIDE - REVLIMID					
021880 001	5635517	Jul 24, 2016	DS	ODE	Dec 27, 2012
	6045501	Aug 28, 2018	U-694		
	6315720	Oct 23, 2020	U-694		
	6555554	Jul 24, 2016	DP		
	6561976	Aug 28, 2018	U-694		
	6561977	Oct 23, 2020	U-694		
	6755784	Oct 23, 2020	U-694		
	6908432	Aug 28, 2018	U-694		
LENALIDOMIDE - REVLIMID					
021880 002	5635517	Jul 24, 2016	DS	ODE	Dec 27, 2012
	6045501	Aug 28, 2018	U-694		
	6315720	Oct 23, 2020	U-694		
	6555554	Jul 24, 2016	DP		
	6561976	Aug 28, 2018	U-694		
	6561977	Oct 23, 2020	U-694		
	6755784	Oct 23, 2020	U-694		
	6908432	Aug 28, 2018	U-694		
LIDOCAINE; TETRACAINE - SYNERA					
021623 001				NC	Jun 23, 2009

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LOPINAVIR; RITONAVIR - KALETRA</u>					
021906 001	5541206	Jul 30, 2013	DS DP	U-688	
	5541206*PED	Jan 30, 2014			
	5635523	Jun 03, 2014		U-688	
	5635523*PED	Dec 03, 2014			
	5648497	Jul 15, 2014	DS DP		
	5648497*PED	Jan 15, 2015			
	5674882	Oct 07, 2014		U-688	
	5674882*PED	Apr 07, 2015			
	5846987	Dec 29, 2012		U-688	
	5846987*PED	Jun 29, 2013			
	5886036	Dec 29, 2012	DP		
	5886036*PED	Jun 29, 2013			
	6037157	Jun 26, 2016		U-688	
	6037157*PED	Dec 26, 2016			
	6703403	Jun 26, 2016		U-688	
	6703403*PED	Dec 26, 2016			
<u>LOVASTATIN; NIACIN - ADVICOR</u>					
021249 001	>A> 7011848	Sep 20, 2013		U-712	
<u>LOVASTATIN; NIACIN - ADVICOR</u>					
021249 002	>A> 7011848	Sep 20, 2013		U-712	
<u>LOVASTATIN; NIACIN - ADVICOR</u>					
021249 003	>A> 7011848	Sep 20, 2013		U-712	
<u>LUBIPROSTONE - AMITIZA</u>					
021908 001				NCE	Jan 31, 2011
<u>MECASERMIN RINFABATE RECOMBINANT - IPLEX</u>					
021884 001	5200509	Apr 06, 2010	DS		
	5681818	Oct 28, 2014		U-697	
<u>MELOXICAM - MOBIC</u>					
020938 001				ODE	Aug 11, 2012
				PED	Feb 11, 2013
<u>MELOXICAM - MOBIC</u>					
020938 002				ODE	Aug 11, 2012
				PED	Feb 11, 2013
<u>MELOXICAM - MOBIC</u>					
021530 001				I-469	Aug 11, 2008
				ODE	Aug 11, 2012
				PED	Feb 11, 2013
				PED	Feb 11, 2009
<u>MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE - VUSION</u>					
021026 001				NP	Feb 16, 2009
<u>MINOXIDIL - MEN'S ROGAINE</u>					
021812 001	6946120	Apr 20, 2019	DP	U-702	NDF Jan 20, 2009
<u>MODAFINIL - PROVIGIL</u>					
020717 001	>A> 4927855	May 22, 2007		U-255	>A> I-449 Jan 23, 2007
	>A> 4927855*PED	Nov 22, 2007			>A> ODE Dec 24, 2005
	>A> RE37516	Oct 06, 2014		U-255	>A> PED Jul 23, 2007
	>A> RE37516*PED	Apr 06, 2015			>A> PED Jun 24, 2006
<u>MODAFINIL - PROVIGIL</u>					
020717 002	>A> 4927855	May 22, 2007		U-255	>A> I-449 Jan 23, 2007
	>A> 4927855*PED	Nov 22, 2007			>A> ODE Dec 24, 2005
	>A> RE37516	Oct 06, 2014		U-255	>A> PED Jul 23, 2007
	>A> RE37516*PED	Apr 06, 2015			>A> PED Jun 24, 2006
<u>MORPHINE SULFATE - KADIAN</u>					
020616 004	5378474	Mar 23, 2010			
<u>MORPHINE SULFATE - KADIAN</u>					
020616 005	5202128	Apr 13, 2010			
	5378474	Mar 23, 2010			
<u>MOXIFLOXACIN HYDROCHLORIDE - AVELOX</u>					
021085 001	4990517	Dec 08, 2011	DS	DP	U-298
	6610327	Oct 29, 2019		DP	U-298

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MOXIFLOXACIN HYDROCHLORIDE - AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER</u>					
021277 001	4990517	Dec 08, 2011	DS DP	U-298	
	6548079	Jul 25, 2020	DP	U-298	
<u>MOXIFLOXACIN HYDROCHLORIDE - VIGAMOX</u>					
021598 001	>A> 4990517	Dec 08, 2011	DS DP	U-709	
	>A> 4990517*PED	Jun 08, 2012			
<u>NELARABINE - ARRANON</u>					
021877 001	5747472	Feb 20, 2013		U-696	
	5747472	Feb 20, 2013		U-695	
	5747472	Feb 20, 2013		U-689	
	5821236	Feb 20, 2013		U-695	
<u>NIACIN - NIASPAN</u>					
020381 001	>A> 7011848	Sep 20, 2013		U-712	
<u>NIACIN - NIASPAN</u>					
020381 002	>A> 7011848	Sep 20, 2013		U-712	
<u>NIACIN - NIASPAN</u>					
020381 003	>A> 7011848	Sep 20, 2013		U-712	
<u>NIACIN - NIASPAN</u>					
020381 004	>A> 7011848	Sep 20, 2013		U-712	
<u>NIACIN - NIASPAN TITRATION STARTER PACK</u>					
020381 005	>A> 7011848	Sep 20, 2013		U-712	
<u>NICOTINE POLACRILEX - NICOTINE POLACRILEX</u>					
077007 001				PC	Aug 21, 2006
<u>NICOTINE POLACRILEX - NICOTINE POLACRILEX</u>					
077007 002				PC	Aug 21, 2006
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>					
019667 001	5753618	May 19, 2015			
	5753618*PED	Nov 19, 2015			
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>					
019667 002	5753618	May 19, 2015			
	5753618*PED	Nov 19, 2015			
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>					
019667 003	5753618	May 19, 2015			
	5753618*PED	Nov 19, 2015			
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>					
019667 004	5753618	May 19, 2015			
	5753618*PED	Nov 19, 2015			
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>					
019667 005	5753618	May 19, 2015			
	5753618*PED	Nov 19, 2015			
<u>OCTREOTIDE ACETATE - SANDOSTATIN LAR</u>					
021008 001	5538739	Jul 23, 2013		ODE	Nov 25, 2005
	5538739*PED	Jan 23, 2014		PED	May 25, 2006
	5639480	Jun 17, 2014			
	5639480*PED	Dec 17, 2014			
	5688530	Nov 18, 2014		U-268	
	5688530*PED	May 18, 2015			
	5922338	Jul 13, 2016			
	5922338*PED	Jan 13, 2017			
	5922682	Jul 13, 2016			
	5922682*PED	Jan 13, 2017			
<u>OCTREOTIDE ACETATE - SANDOSTATIN LAR</u>					
021008 002	5538739	Jul 23, 2013		ODE	Nov 25, 2005
	5538739*PED	Jan 23, 2014		PED	May 25, 2006
	5639480	Jun 17, 2014			
	5639480*PED	Dec 17, 2014			
	5688530	Nov 18, 2014		U-268	
	5688530*PED	May 18, 2015			
	5922338	Jul 13, 2016			
	5922338*PED	Jan 13, 2017			
	5922682	Jul 13, 2016			
	5922682*PED	Jan 13, 2017			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OCTREOTIDE ACETATE - SANDOSTATIN LAR</u>					
021008 003	5538739	Jul 23, 2013		ODE	Nov 25, 2005
	5538739*PED	Jan 23, 2014		PED	May 25, 2006
	5639480	Jun 17, 2014			
	5639480*PED	Dec 17, 2014			
	5688530	Nov 18, 2014	U-268		
	5688530*PED	May 18, 2015			
	5922338	Jul 13, 2016			
	5922338*PED	Jan 13, 2017			
	5922682	Jul 13, 2016			
	5922682*PED	Jan 13, 2017			
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>					
021849 001	>A> 6489346	Jul 16, 2016	DS DP	U-588	
	>A> 6645988	Jul 16, 2016	DS DP		
	>A> 6699885	Jul 16, 2016		U-588	
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>					
021849 002	>A> 6489346	Jul 16, 2016	DS DP	U-588	
	>A> 6645988	Jul 16, 2016	DS DP		
	>A> 6699885	Jul 16, 2016		U-588	
<u>OXALIPLATIN - ELOXATIN</u>					
021492 001	5420319	Aug 09, 2016	DS		
<u>OXALIPLATIN - ELOXATIN</u>					
021492 002	5420319	Aug 09, 2016	DS		
<u>OXALIPLATIN - ELOXATIN</u>					
021759 001	5420319	Aug 08, 2016	DS		
<u>OXALIPLATIN - ELOXATIN</u>					
021759 002	5420319	Aug 08, 2016	DS		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>					
020667 001	4843086	Jun 27, 2006		U-231	
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>					
020667 002	4843086	Jun 27, 2006		U-231	
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>					
020667 003	4843086	Jun 27, 2006		U-231	
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>					
020667 004	4843086	Jun 27, 2006		U-231	
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>					
020667 005	4843086	Jun 27, 2006		U-231	
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>					
020667 006	4843086	Jun 27, 2006		U-231	
<u>QUETIAPINE FUMARATE - SEROQUEL</u>					
020639 006	4879288	Sep 26, 2011	DS DP	U-550	
<u>QUETIAPINE FUMARATE - SEROQUEL</u>					
020639 007	4879288	Sep 26, 2011	DS DP	U-550	
<u>RALOXIFENE HYDROCHLORIDE - EVISTA</u>					
020815 001	RE38968	Jul 28, 2012		U-662	
	RE38968	Jul 28, 2012		U-657	
	>A> RE39049	Jul 28, 2012		U-662	
	>A> RE39049	Jul 28, 2012		U-657	
	>A> RE39050	Mar 02, 2014		U-662	
	>A> RE39050	Mar 02, 2014		U-657	
<u>RANOLAZINE - RANEXA</u>					
021526 002	4567264	May 18, 2006	DS	NCE	Jan 27, 2011
	6303607	May 27, 2019		U-705	
	6369062	May 27, 2019		DP	
	6479496	May 27, 2019		U-705	
	6503911	May 27, 2019		DP	
	6525057	May 27, 2019		U-705	
	6562826	May 27, 2019		U-705	
	6617328	May 27, 2019		DP	
	6620814	May 27, 2019		U-705	
	6852724	May 27, 2019		U-705	
	6864258	May 27, 2019		U-705	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RISEDRONATE SODIUM - ACTONEL</u>					
020835 001				M-52	Jan 24, 2009
<u>RISEDRONATE SODIUM - ACTONEL</u>					
020835 002				M-52	Jan 24, 2009
<u>RISEDRONATE SODIUM - ACTONEL</u>					
020835 003				M-52	Jan 24, 2009
<u>SALMETEROL XINAFOATE - SEREVENT</u>					
020236 001	4992474	Feb 12, 2008			
	4992474*PED	Aug 12, 2008			
	5126375	Feb 12, 2008			
	5126375*PED	Aug 12, 2008			
	5225445	Feb 12, 2008	U-182		
	5225445*PED	Aug 12, 2008			
<u>SALMETEROL XINAFOATE - SEREVENT</u>					
020692 001	4992474	Feb 12, 2008			
	4992474*PED	Aug 12, 2008			
	5126375	Feb 12, 2008			
	5126375*PED	Aug 12, 2008			
	5225445	Feb 12, 2008	U-211		
	5225445*PED	Aug 12, 2008			
<u>SELEGILINE - EMSAM</u>					
021336 001	>A> RE34579	Aug 18, 2007	DS DP	U-711 NDF	Feb 27, 2009
<u>SELEGILINE - EMSAM</u>					
021336 002	>A> RE34579	Aug 18, 2007	DS DP	U-711 >A> NDF	Feb 27, 2009
<u>SELEGILINE - EMSAM</u>					
021336 003	>A> RE34579	Aug 18, 2007	DS DP	U-711 >A> NDF	Feb 27, 2009
<u>SEVELAMER HYDROCHLORIDE - RENAGEL</u>					
021179 001	>A> 7014846	Aug 11, 2013	DP	U-246	
<u>SEVELAMER HYDROCHLORIDE - RENAGEL</u>					
021179 002	>A> 7014846	Aug 11, 2013	DP	U-246	
<u>SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE - OSMOPREP</u>					
021892 001				>A> NP	Mar 16, 2009
<u>SORAFENIB TOSYLATE - NEXAVAR</u>					
021923 001				ODE	Dec 20, 2012
<u>SUNITINIB MALATE - SUTENT</u>					
021938 001	6573293	Feb 15, 2021	DS DP	U-703 NCE	Jan 26, 2011
<u>SUNITINIB MALATE - SUTENT</u>					
021938 002	6573293	Feb 15, 2021	DS DP	U-703 NCE	Jan 26, 2011
<u>SUNITINIB MALATE - SUTENT</u>					
021938 003	6573293	Feb 15, 2021	DS DP	U-703 NCE	Jan 26, 2011
<u>TACROLIMUS - PROGRAF</u>					
050708 001				>A> ODE	Mar 29, 2013
<u>TACROLIMUS - PROGRAF</u>					
050708 002				>A> ODE	Mar 29, 2013
<u>TACROLIMUS - PROGRAF</u>					
050708 003				>A> ODE	Mar 29, 2013
<u>TACROLIMUS - PROGRAF</u>					
050709 001				>A> ODE	Mar 29, 2013
<u>TERIPARATIDE RECOMBINANT HUMAN - FORTEO</u>					
021318 001	6977077	Aug 19, 2019		U-597	
<u>THYROTROPIN ALFA - THYROGEN</u>					
020898 001				M-53	Jan 23, 2009
<u>TREPROSTINIL SODIUM - REMODULIN</u>					
021272 001	5153222	Oct 06, 2014		U-455	
<u>TREPROSTINIL SODIUM - REMODULIN</u>					
021272 002	5153222	Oct 06, 2014		U-455	
<u>TREPROSTINIL SODIUM - REMODULIN</u>					
021272 003	5153222	Oct 06, 2014		U-455	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL SODIUM - REMODULIN</u>					
021272 004	5153222	Oct 06, 2014	U-455		
<u>ZANAMIVIR - RELENZA</u>					
021036 001				>A> I-491	Mar 29, 2009
<u>ZOLEDRONIC ACID - ZOMETA</u>					
021223 001	>A> 4939130	Sep 02, 2012	DS DP U-53		
<u>ZOLEDRONIC ACID - ZOMETA</u>					
021223 002	>A> 4939130	Sep 02, 2012	DS DP U-53		

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents submitted on FDA Form 3542 and listed after August 18, 2003 will have one to three patent codes indicating specific patent claims as submitted by the sponsor:

DS = Drug Substance claim

DP = Drug Product claim

U and number = Method of Use claim (may be multiple). Specific Method of use claims are listed at <http://www.fda.gov/cder/orange/patex.htm>

3. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

4. *PED and PED represent pediatric exclusivity. Patents with pediatric exclusivity granted after August 18, 2003 will be indicated with *PED as was done prior to August 18, 2003. Patents with *PED added after August 18, 2003 will not contain any information relative to the patent itself other than the *PED extension. Information related specifically to the patent will be conveyed on the original patent only.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 25th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of exclusivity terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>